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Pediatric rheumatology is a young speciality, and research in the field has been limited 
until the last few decades (1, 2). Traditionally children with rheumatic diseases have 
been treated by adult rheumatologists, while the field is gradually more dominated by 
pediatricians. In northern Norway the first clinical service was established at the 
pediatric department by professor Gudmund Marhaug in the 1970’s, after training in 
Lund in Sweden. Together with Marite Rygg he developed a full clinical care with 
multi-disciplinary team for all children with rheumatic diseases from Finnmark and 
Troms, the two northernmost regions of Norway. In addition to the clinical service, 
research was initiated, first in basic science, later in epidemiological clinical research 
in collaboration with other Nordic centers. The present study has developed from this 
Nordic collaboration. Important initiative to establish the Nordic JIA cohort was taken 
by Anders Fasth and Boel Andersson Gäre, being supervisors of Lillemor Berntson in 
her PhD on incidence and classification issues in the Nordic JIA cohort.      
 
My personal interest originates from several years of clinical experience with JIA in 
children. In spite of recent advances in medical treatment, there is still no cure for JIA. 
The children have to live with the disease for many years, taking medicines and 
experiencing waxing and waning disease activity. I am impressed by the children’s 
and their families’ way of coping with this chronic disease. I am curious about the 
outcome, and I am also intrigued by the complexity of the disease.  
 
Treatment and expectations for remission have changed even during my limited time 
working in this field. There are ongoing changes of established “truths” in medicine, 
reminding us to keep up critical thinking around common practices in clinical care. 
During these years our knowledge regarding JIA has increased due to high-quality 
basic and clinical research. My hope is that our study can contribute by one little piece 
in the big puzzle of understanding more about predictive factors, disease activity and 
outcome in JIA.  
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This thesis is based on the Nordic juvenile idiopathic arthritis (JIA) cohort study. In a 
multi-centre population-based setting a prospective followup of juvenile idiopathic 
arthritis (JIA) was performed. Pediatric rheumatology centers in Denmark, Finland, 
Norway and Sweden included children with newly diagnosed JIA during a 3.5 year 
period starting January 1st 1997. The study was focused on outcome in terms of 
disease characteristics, course, activity and damage the first eight years after onset. 
Validation of the Juvenile arthritis disease activity score (JADAS) was performed. 
Incidence, clinical risk factors and biomarkers of JIA-associated uveitis were also 
studied. 
 
The first paper described outcome in the Nordic JIA cohort eight years after disease 
onset. Of the 500 children included at baseline, 440 children (88%) were followed 
more than 7 years. A change in JIA category during disease course was observed in 
10.8% of the children, in addition to extended oligo-arthritis developing in one-third of 
the oligoarticular group. Disease activity was mostly mild, with low impact on daily 
life in patient-reported health-related quality of life (HRQoL). However, the chronicity 
of the disease was demonstrated as 57.6% of the children were not in medication-free 
remission at the final visit.  
  
In the second paper the JADAS was validated with C-reactive protein (CRP) replacing 
erythrocyte sedimentation rate (ESR) as an inflammatory marker. JADAS based on 
CRP correlated closely with the version based on ESR. JADAS was shown to be a 
feasible and valid tool in assessing disease activity in children with JIA in a 
population-based setting.  
 
In the third paper the predictive value of biomarkers and clinical characteristics at 
disease onset in regard to development of uveitis was studied in a pilot study of the 
Norwegian cohort of 100 children with JIA. During a mean observation time of 7 
years, 16 children developed chronic uveitis. Antihistone antibodies (AHA) ≥8 U/ml, 
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anti-nuclear antibodies detected by immunofluoresence (IF) ≥320 titer and young age 
at disease onset were significant predictors of uveitis development in JIA.  Presence of 
ANA detected by enzyme-linked immunosorbent assays (ELISA) showed no 
association to development of uveitis, and should never be used to determine 
frequencies of eye examinations in children with JIA.  
 
The main findings of this study support the understanding of JIA as a long-term 
chronic disease.  Further, we found that ILAR categories changed over time, JADAS 
based on C-reactive protein was a valid tool for evaluation of JIA disease activity in a 
population-base setting, and also that predicting uveitis in JIA remains a challenge.   
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1 INTRODUCTION 
1.1 Chronic arthritis in children 
Visual arts may tell more than scientific descriptions, and a painting by Sandro 
Boticelli “Portrait of a youth” from 1483 shows a young boy with swollen finger joints 
who probably had chronic arthritis (1, 3). The first recognized medical description of 
chronic arthritis in childhood is, according to Schaller, found in an English textbook of 
pediatrics by Thomas Phaer “The book of Chyldren” from 1545 referring to the 
“stiffness of limes” thought to be a result of exposing children to the cold (1, 4). 
Childhood arthritis cases are reported by Cornil in 1864, Charcot in 1866, Bouchet in 
1875, all in Paris, and Lewis-Smith and Garrod from New York and London in 1876. 
The Brasilian Moncorvo reported from Paris in 1880, West from London in 1881, and 
Marfan from Paris in 1896 (1, 5-11). In a thesis from Paris in 1890, Diamantberger 
describes that chronic arthritis in children differs from adults as it often starts in large 
joints and may involve other organs as the eye (iritis) and the heart (pericarditis) (12, 
13). He also stated that the prognosis is better than in adults although growth 
disturbances in the jaw (micrognathia) may occur, and suggests both salicylic acid 
drug therapy and physiotherapy (12, 13). Even if preceded by Diamantberger, Georg 
Friedrich Still is famous for his publication in 1897 with case descriptions “On a form 
of chronic arthritis in children”, where he also suggests that childhood arthritis is a 
separate disease entity, and gives a detailed description on systemic juvenile arthritis 
(14, 15). Chronic arthritis in children was then for many years named Still’s disease, 
even though G.F. Still’s later publications were on other childhood diseases, and he 
was among the first to describe attention deficit disorder (ADD) in children (16).  The 
term Still’s disease has later been used for the systemic category of JIA, and even 
today the adult form of systemic JIA is called Still’s disease.  
 
1.1.1 Definition of arthritis 
Arthritis is an inflammatory condition in a joint, and the word arthritis is derived from 
“arthron”, the Greek word for joint (17). Arthritis is defined as a clinical finding of 
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swelling within a joint, or limitation in the range of joint movement with joint pain or 
tenderness, excluding primarily mechanical disorders and other identifiable causes 
(18).  
 
1.1.2 Differential diagnoses of arthritis in children 
When a child presents with a swollen joint, many different conditions must be 
considered (19, 20). Septic arthritis and osteomyelitis are diseases in urgent need of 
antibacterial treatment and must always be ruled out as differential diagnoses in any 
child presenting with a joint swelling or a limp (21-23). Other infectious, para- and 
post-infectious forms of arthritis should also be considered (20). Transient coxitis is 
the most common form of arthritis in young children (24, 25). Trauma, child abuse, 
malignancy and hematological conditions as bleeding disorders, sickle-cell anemia, 
and leukemia may present with painful joint swellings (21, 24, 26-28). Chronic 
arthritis in children can also be a manifestation of other auto-immune diseases, auto-
inflammatory syndromes, and a wide range of other inborn or acquired conditions (27, 
29, 30). Other identifiable causes of arthritis should be ruled out by a thorough history, 
clinical examination and diagnostic work-up before juvenile idiopathic arthritis is 
diagnosed in a child (26). 
 
1.1.3 Classification of chronic childhood arthritis 
During the last decades several terms and classifications have been used for this 
diverse clinical entity encompassing different disease categories of childhood arthritis 
(31). Previously, the terms juvenile rheumatic arthritis (JRA) and juvenile chronic 
arthritis (JCA) was used. In 1973 classification criteria for JRA were published by the 
American Rheumatism Association (ARA) (later named American College of 
Rheumatology (ACR)). JRA was defined as an idiopathic arthritis of minimum 6 
weeks’ duration in an individual <16 years of age, and three onset types were 
described; the systemic, the pauciarticular and the polyarticular forms (32). In 1977 
criteria for JCA were proposed by the European League Against Rheumatism 
(EULAR), defining JCA as idiopathic arthritis of minimum 3 months’ duration in the 
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same age group (33). The term JCA also included the categories of juvenile ankylosing 
spondylitis, arthritis associated with inflammatory bowel disease (IBD), and juvenile 
psoriatic arthropathy, while these were defined as separate entities not included in the 
JRA criteria. JRA has been widely used in the United States and Canada, while the 
term JCA was mainly used in Europe. Finally, universal agreement has been reached 
since the 1990’s on the classification criteria of juvenile idiopathic arthritis (JIA) 
(Table 1) (18, 34).  
 
Juvenile idiopathic arthritis is, according to the International League Against 
Rheumatism (ILAR), defined as swelling within a joint, or limitation in the range of 
joint movement with joint pain or tenderness, which persists for at least 6 weeks in a 
child under 16 years of age, observed by a physician, and not due to primarily 
mechanical disorders or to other identifiable causes (18). The aim of the classification 
criteria is to be useful both in the pragmatic setting of clinical everyday work and in 
providing the precise definitions needed for research. There is an ongoing discussion 
how to improve the disease descriptors in order to refine classification and identify 
more homogenous disease groups for both clinical and research purposes. The ILAR 
classification criteria are stated to be a “work in progress” rather than a static 
framework (18). The criteria have been revised twice, latest in 2001 (18, 34). Heredity 
for psoriasis in second degree relatives was removed in 2001 as an exclusion criterion, 
because a disproportionately high number of children were otherwise designated to the 
undifferentiated arthritis category (18, 35). 
  
Juvenile idiopathic arthritis is the most common chronic rheumatic disease of 
childhood (26). The clinical spectrum spans from time-limited monoarthritis to 
ongoing aggressive polyarticular disease, and may include severe systemic features or 
sight-threatening uveitis. The broad spectrum in symptoms and signs, clinical findings 
and course, implies that JIA is probably not one specific disease, but rather a group of 
disease entities. There is no simple diagnostic test, but the diagnosis of JIA is based on 
a combination of clinical findings, duration and exclusion of other conditions. The 
term JIA is still used for adult patients that have had juvenile onset of a chronic 
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idiopathic arthritis. The varying definitions used in different time periods and parts of 
the world may partly explain the diverging results both in incidence and disease 
outcome in studies of chronic childhood arthritis. The universal acceptance of the 
ILAR classification criteria for JIA is a giant step forward and an important 
prerequisite to gain new and valid knowledge on the disease.
 
Table 1.  International League of Associations for Rheumatology (ILAR) classification of JIA.*  
Category Definition Exclusions 
 
Systemic onset JIA 
 
Arthritis in one or more joints with, or preceded by, fever of at least 2  
weeks’ duration that is documented to be daily (‘‘quotidian†’’) for at  
least 3 days and accompanied by one or more of the following: 
1. Evanescent (non-fixed) erythematous rash  
2. Generalised lymph node enlargement 
3. Hepatomegaly and/or splenomegaly 
4. Serositis‡ 
 
A. Psoriasis or a history of psoriasis in the patient or  
a first-degree relative 
B. Arthritis in an HLA-B27 positive male beginning  
after the 6th birthday 
C. Ankylosing spondylitis, enthesitis-related arthritis, 
sacroiliitis with inflammatory bowel disease, Reiter’s 
syndrome, or acute anterior uveitis, or a history of 
one of these disorders in a first-degree relative 
D. The presence of IgM rheumatoid factor on at least 




Arthritis affecting 1–4 joints during the first 6 months of disease. Two 
subcategories are recognised: 
1. Persistent oligoarthritis: affecting not more than 4 joints throughout  
the disease course 
2. Extended oligoarthritis: affecting a total of more than 4 joints after  
the first 6 months of disease 
 
A–D above, plus 




Arthritis affecting 5 or more joints during the first 6 months of disease;  
a test for RF is negative 
 




Arthritis affecting 5 or more joints during the first 6 months of disease;  
2 or more tests for RF at least 3 months apart during the first 6 months  
of disease are positive 
 
















Arthritis and psoriasis, or arthritis and at least 2 of the following:  
1. Dactylitis§ 
2. Nail pitting** and onycholysis 
3. Psoriasis in a first-degree relative 
 




Arthritis and enthesitis††, or arthritis or enthesitis with at least 2 of the 
following: 
1. The presence of or a history of sacroiliac joint tenderness and/or 
inflammatory lumbosacral pain‡‡ 
2. The presence of HLA-B27 antigen 
3. Onset of arthritis in a male over 6 years of age 
4. Acute (symptomatic) anterior uveitis 
5. History of ankylosing spondylitis, enthesitis-related arthritis, 
sacroiliitis with inflammatory bowel disease, Reiter’s syndrome or 
acute anterior uveitis in a first-degree relative 
 
A, D, E 
 
 
Undifferentiated arthritis       
 




*Adapted from McCann LJ et al in Arch Dis Child Educ Pract Ed 2006 and Petty R et al in J Rheumatol 1994 (18, 36).  
†Quotidian fever is defined as a fever that rises to 39˚C once a day and returns to 37˚C between fever peaks. 
‡Serositis refers to pericarditis and/or pleuritis and/or peritonitis. 
§Dactylitis is swelling of one or more digits, usually in an asymmetrical distribution, which extends beyond the joint margin. 
**A minimum of 2 pits on any one or more nails at any time. 
††Enthesitis is defined as tenderness at the insertion of a tendon, ligament, joint capsule, or fascia to bone. 
‡‡Inflammatory lumbosacral pain refers to lumbosacral pain at rest with morning stiffness that improves on movement.
1.1.4 JIA categories  
According to the ILAR classification criteria for JIA, seven different categories are 
described in addition to an undifferentiated group (Table 1) (18). 
 
1.1.4.1   Systemic JIA 
The systemic form of JIA is characterized by high spiking fever, a non-fixed 
erythematous rash, and systemic features as liver, spleen or general lymph node 
enlargement (37). Fluid may accumulate in the serosal linings of the heart, the lungs or 
the abdomen due to inflammation. Arthritis may be present at onset or develop later, 
and the diagnosis may be difficult to ascertain if the arthritis present late (26). 
Although monocyclic limited disease is described in almost half of the children, the 
most severe polyarticular disease courses are also seen is this group (38).    
 
1.1.4.2   Oligoarthritis persistent 
Oligoarticular arthritis is defined as involvement of less than five joints during the first 
six months of disease. If the number of involved joints remains less than five during 
the following disease course, then oligoarticular persistent disease is present (18). 
There are several exclusion criteria regarding psoriasis, enthesitis-related and systemic 
features (Table 1). Although a limit of five joints may be arbitrary, this category is 
associated with the best prognosis regarding milder disease course and a higher rate of 
remission (38). 
  
1.1.4.3   Oligoarthritis extended 
From 20-50% of the children with oligoarthritis the first six months will later have 
involvement of five or more joints, and this group is defined to have extended disease 
(39-41). Exclusion criteria are applied as for persistent oligoarthritis (18). The disease 
activity is often more severe, with a course and outcome closer to polyarthritis rather 
than the persistent oligoarticular category (39). 
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1.1.4.4   Polyarthritis rheumatoid factor-negative 
Polyarthritis is defined as involvement of at least five joints during the first six months 
of disease (18). There are also several exclusion criteria regarding psoriasis, enthesitis-
related and systemic features (Table 1). This category is characterized by a negative 
test for rheumatoid factor, and tends to have ongoing disease activity and lower rates 
of remission, in line with the oligoarticular extended category (42). 
 
1.1.4.5   Polyarthritis rheumatoid factor-positive 
As above polyarthritis is defined as involvement of at least five joints during the first 
six months of disease, with several exclusion criteria (Table 1). In addition this 
category is characterized by the presence of rheumatoid factor (RF). Two tests should 
be positive taken at least three months apart (18). Rheumatoid factor-positive 
polyarticular disease is mostly found in older girls (26). The age definition of JIA up to 
16 years may seem somewhat arbitrary, and this category may represent a subset with 
an early-onset of adult seropositive type rheumatoid arthritis (43). The few children 
that belong to this category are shown to often have an ongoing and destructive 
arthritis, with a more severe prognosis than rheumatoid factor-negative polyarthritis 
(44-47).  
 
1.1.4.6   Psoriatic arthritis 
Arthritis in combination with psoriasis is defined as psoriatic arthritis (18). Psoriasis 
may develop many years later than the arthritis or vice versa (48). If psoriasis is not 
present, the child is also defined to have psoriatic arthritis if there is heredity for 
psoriasis, presence of finger swellings (dactylitis) and/or characteristic nail changes 
(18). The psoriasis must be diagnosed by a physician. 
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1.1.4.7   Enthesitis-related arthritis 
Enthesitis is an inflammation of the area of insertion of a tendon, ligament, joint 
capsule or fascia to bone (18). Typical localizations of enthesitis are the heel insertion 
of the achilles tendon and the tibial insertion of the patellar tendon below the knee. 
Inflammatory low back pain, sacroileitis and acute uveitis are also common features. 
This is the only JIA category with a majority of boys, and there is a close association 
to HLA-B27 (26). Enthesitis-related arthritis has somewhat different inclusion criteria 
than the previously used terms juvenile ankylosing spondylitis (JAS), seronegative 
enthesopathy and arthropathy (SEA) and juvenile spondylarthropathy (JSp) (49).   
  
1.1.4.8   Undifferentiated arthritis 
In order to define as homogeneous groups as possible, there are exclusion criteria for 
all JIA categories. Those that do not fulfill any JIA category due to the exclusion 
criteria, or fulfill criteria of more than one category, are defined to have 
undifferentiated arthritis (18). In this way a child may first fulfill the criteria of one 
category; for example the oligoarticular persistent, if one of the parents develop 
psoriasis then undifferentiated arthritis is the correct category as this heredity is an 
exclusion criterion. If the child later develops nail pitting or dactylitis, then the criteria 
of psoriatic arthritis are fulfilled. In this way the category may change over time as the 
characteristics of the disease reveal. 
 
1.1.5 Disease biomarkers and predictors of outcome 
In a heterogeneous disease group as JIA, predictors of disease course and outcome are 
of crucial value. Biomarkers are any substance, structure or process that can be 
measured in bio-specimens and may influence, explain or predict health-related 
outcomes (50). Clinical findings may in the same way as biomarkers predict certain 
outcomes. Clinical characteristics and inflammation markers at onset, early disease 
course, early radiographic findings, response to therapy, and autoantibodies have been 
of particular interest as potential predictors in JIA (46, 51-53). ESR and CRP are 
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unspecific inflammation markers often used to monitor disease activity in JIA. 
Autoantibodies are directed against “self”, that is antibodies produced by the 
individual’s adaptive immune system against its own body components.  
 
1.1.5.1   CRP  
C-reactive protein is part of the acute phase response to tissue injury. The name 
originates from the discovery of CRP as a serum substance reacting to infection with 
the capsular (C-) polysaccharide of Streptococcus Pneumoniae (54). It is a pentameric 
protein produced in the liver, and considered as part of the body’s innate immune 
system (55). Inflammation is a key regulator of CRP synthesis. CRP is extensively 
used as a marker of inflammation. In an acute infection a high value indicates bacterial 
agents, while viral infections usually have lower values. CRP has physiologic 
functions through binding to membranes of bacteria and damaged cells, activating the 
classical, but also modifying the alternative-pathway complement system (54, 55). 
Elevated CRP is associated with active synovitis in JIA, and CRP may be used to 
monitor effect of treatment (56). CRP is included in recent treatment algorithms as 
predictors of severe disease course (46, 56).   
 
1.1.5.2   ESR 
The erythrocyte sedimentation rate is simply the rate at which red blood cells sediment 
when blood is placed in a vertical column for one hour. It is an indirect marker of 
blood levels of fibrinogen, other acute phase proteins and immunoglobulin (55).  This 
presence of various cationic proteins promotes the formation of “roleaux” structures 
increasing the sedimentation rate (57). The phenomenon was already known in 
medicine in ancient Greece. The test has later been described and in periods named 
after the Polish physician Biernacki in 1897, and the Swedish physicians Fähraeus and 
Westergren (58, 59). High ESR is commonly found in infections, anemia, 
malignancies and rheumatic diseases. Early and persistently elevated ESR in JIA has 
been shown to predict adverse outcome in several studies (44, 45, 49, 60). 
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1.1.5.3   Rheumatoid factor and anti-citrullinated protein antibodies  
Rheumatoid factor (RF) and anti-citrullinated protein antibodies (ACPA) are 
autoantibodies found in a minority of children with JIA, although they are commonly 
found in adult rheumatoid arthritis (61-64). RF was first described by the Norwegian 
physician Waaler in 1940 as a factor that clotted sera in adults with rheumatoid 
arthritis (65). ACPA are antibodies against the modified amino-acid citrullin. ACPA 
are produced locally in the inflamed synovium, and serum levels are measured by 
ELISA tests for anti-CCP (66). Both in children and adults these autoantibodies are 
reported to be associated with a more severe prognosis (45, 53, 61). In adult RA, some 
recent studies have shown that ACPA has higher diagnostic and prognostic value than 
RF (61, 67-70). In older children with chronic arthritis the presence of RF and/ or 
ACPA may indicate an early-onset of adult rheumatoid arthritis even if the child is less 
than 16 years of age (43).  
 
1.1.5.4   Antinuclear antibodies and antihiston antibodies 
Antinuclear antibodies (ANA) are autoantibodies against intracellular nuclear 
antigens. ANA and several antigen-specific nuclear antibodies are present in many 
rheumatic diseases (71). Anti-DNA and anti-SM is among the antigen-specific 
subtypes of ANA, listed among the 11 ACR classification criteria for SLE (72, 73). 
The presence of circulating ANA in JIA is well documented, and the prevalence varies 
in different studies, probably due to both ethnic differences and laboratory 
methodology (74). The sub-specificities of ANA in JIA have not been fully elucidated 
in spite of several studies (75-77).  Traditionally ANA has been detected by 
immunofluorescence method using Hep-2 cells (IF-ANA) (71, 78-80). This method 
has been criticized for lack of specificity, it is highly operator-dependent and 
satisfactory standardization has been difficult to achieve (79). Enzyme-linked 
immunosorbent assays (ELISA) enables automated identification of antigen-specific 
ANA. ELISA-ANA is increasingly used, but is rarely positive in JIA (74).  
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Histones are basic DNA-binding proteins that are subcomponents of chromatin, and 
arrange in highly organized nucleosomal particles. The five histone molecules enable 
formation of the double helix DNA, and the core histones (H2A, H2B, H3, H4) are 
evolutionary highly conserved between species (81). New interest for histones has 
emerged through the recent findings in epigenetics (82). Antihistone antibodies are 
among the ANA subtypes identified in subsets of children with JIA (75, 81, 83-88). 
AHA are in some studies associated with early-onset JIA, oligoarticular onset and 
uveitis (83, 88). 
 
1.1.6 Etiology 
It seems clear that JIA is a multi-factorial disease, although etiology remains largely 
unknown (37, 38, 89). There is strong evidence of genetic factors conferring an overall 
susceptibility to JIA (90-94). In other words JIA is viewed as a complex polygenic 
disease (95). The human major histo-compatibility complex (MHC) plays an important 
role in the body’s recognition of self, and it is closely linked to autoimmunity. 
Associations with multiple MHC-class II molecules and with specific genes have been 
shown for certain categories of JIA (43, 49, 96-100). The human leucocyte antigen 
B27 (HLA-B27) is a MCH-class I molecule found more commonly in JIA than in 
healthy children (62). HLA-B27 shows a strong association to enthesitis-related 
arthritis (62, 101, 102). In addition, epigenetics has recently been shown to play an 
important role in autoimmunity, and may also be involved in the pathogenesis of JIA 
(89, 103).  
 
Environmental factors as infections and vaccinations have been suggested as triggers 
of onset and relapses in JIA, but no single trigger has been identified (89, 104). A 
sequence of triggering events preceding onset of JIA in a genetically predisposed 
individual seems likely (89, 105). The range of triggers may cause a break in the self-
tolerance of the individual. A disturbed balance between pro-inflammatory effector 
cells and anti-inflammatory regulatory cells may result in synovial inflammation in the 
joints (37). Auto-reactive T-lymphocytes play key roles, and T-helper17 cells are 
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among the pro-inflammatory lymphocytes that are selectively recruited from the blood 
and found in synovial fluid in JIA (89). These effector T cells in JIA are recently 
shown to be resistant to immunoregulation by functional regulatory T-lymphocytes, 
possibly contributing to the ongoing inflammation (106, 107).  
 
Hormonal factors may play a role as increased levels of prolactin have been detected 
in children with JIA and ANA positivity (108). A study of pregnancies in patients with 
JIA showed that a majority experienced improvement of arthritis during pregnancy, 
but disease flares were common after birth (109). There is some evidence that stromal 
cells and mechanical stress may play a role in the pathophysiology of enthesitis in 
spondyloarthropathy and psoriatic arthritis (110-112). The role of diet is unclear in 
JIA. In adult rheumatology, however, intake of oily fish is associated with a modest 
decreased risk of developing rheumatoid arthritis (113). In rheumatoid arthritis in 
adults large scale epidemiologic studies have shown genetic susceptibility for 
environmental factors such as smoking (114-116). There is also some evidence that 
maternal smoking in pregnancy increase the risk of chronic childhood arthritis in their 
children (117). 
 
Systemic JIA seems in many ways different from other JIA categories, and has lately 
been suggested to belong to the group of autoinflammatory rather than the 
autoimmune diseases (37, 118). This is suggested by the excellent clinical response to 
anti IL-1 and IL-6 treatment and lack of autoantibodies or antigen-specific T-cells 
(37). The autoinflammatory diseases arise primarily from defects in the innate 
immune-system characterized by specific genetic associations and prominent systemic 
features (118-120). 
 
1.1.7 Symptoms and clinical findings 
A limp and morning stiffness, joint swelling, pain and restricted movement in one or 
more joints are the most common symptoms and clinical findings at onset of JIA (38). 
General malaise, fever and exanthema may occur (26). While localized symptoms as 
 
joint stiffness and pain dominates in older children, general symptoms 
appetite, irritability and increased need for rest and 
the onset in early childhood (21)
of inflammation as anemia, thrombocytosis, raised ESR and/or CRP are comm
findings. Specific immunological markers as ANA, RF, ACPA and HLA
found, but are not a prerequisite for the diagnosis and is not present in many children 
with JIA (18, 56, 76, 121-125)
 
1.1.8 Uveitis 
Uveitis is the most common extraarticular ma
of children with JIA (126-131)
eye (iris, ciliary body and choroid) (F
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Uveitis is described as anterior, intermediate, posterior or pan-uveitis depending on the 
localization of the inflammation in the uvea. Uveitis is also defined according to the 
onset type, duration and course (Table 2) (132). In addition to the association to JIA, 
uveitis may be idiopathic or associated to other rheumatic or infectious diseases (132-
134). The JIA-associated uveitis is almost always an inflammation of the anterior uvea 




Table 2. The Standardization of uveitis nomenclature (SUN) Working Group Descriptors of 
Uveitis*. 
Category Descriptor Comment 
Onset Sudden  
 Insidious  
   
Localization Anterior  
 Intermediate   
 Posterior  
 Panuveitis  
   
Duration Limited ≤3 months duration 
 Persistent >3 months duration 
   
Course   Acute Episode characterized by sudden onset 
and limited duration 
 Recurrent Repeated episodes separated by periods of inactivity 
without treatment ≥3 months in duration 
 Chronic Persistent uveitis with relapse in <3 
months after discontinuing treatment 
*Adapted from Jabs et al in Am J Ophtalmol 2005 (132). 
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The acute form of uveitis usually has a sudden onset, limited duration, and presents 
with a painful, red eye in older children with JIA (130). Acute uveitis is often 
associated with a positive HLA-B27 antigen and enthesitis-related arthritis, and is 
usually diagnosed promptly because it has obvious clinical symptoms and signs (126). 
Chronic insidious and asymptomatic uveitis is the most common form of uveitis in JIA 
(126, 137). Chronic uveitis is usually without symptoms until reduced vision or pain 
occurs as a consequence of the complications of the inflammation.  
 
Traditionally early-onset arthritis, oligoarticular onset, presence of ANA, and female 
gender has been associated with increased risk of development of uveitis (Table 3). 
Young age at onset of arthritis is the most important risk factor for development of 
chronic uveitis in JIA, and an association between uveitis and early-onset arthritis has 
been a consistent finding since the first report in 1957 (138-140). Increased risk of 
uveitis has been reported for the category of oligoarticular JIA, but several recent 
studies show the same risk in polyarticular compared to oligoarticular categories (129, 
141). Uveitis is rare in systemic JIA (142). Presence of ANA and female gender has 
been reported to be associated to uveitis (141). However, there are recent studies 
showing no increased risk in ANA positive children (143, 144). Several studies have 
also shown no predilection for females to develop uveitis, when it is taken into account 
the higher number of girls with JIA in general (127, 129, 143). The risk of uveitis 
development may be strongly related to young age at onset and ANA positivity, in 
girls, but not in boys, independent of JIA category (145). Early diagnosis and 
treatment of uveitis is essential to avoid complications leading to reduced vision or 
blindness (135, 143, 146, 147). The most frequent complications of JIA-associated 
uveitis are cataract, glaucoma, band keratopathy, synecchiae, and macular and/ or 
optic disc oedema (126, 127, 142, 148, 149). Phtisis bulbi may occur in the end stage 
(127, 143). Even in recent publications the rate of complications remains high (Table 
3). As uveitis is mostly asymptomatic, regular slit-lamp examination at specific 
intervals in all children with JIA is strongly recommended (143). Different screening 
programs are suggested based on the reported risk factors (127, 143, 146, 150). 













Factors associated with development of uveitis 
Early-onset 
arthritis 
Oligoarthritis ANA Female 
 
Kotaniemi 2001  
n = 426  
Prospective cohort, 
tertiary center 
5 24 24 + - + - 
         
Minden 2002  




and tertiary center 
16 14 48 n.a. - n.a. n.a. 
         
Packham 2002  
n = 259 
Retrospective , 
tertiary center 
28 22 n.a. n.a. n.a. n.a. n.a. 
         
Flato 2003 
n = 268 
Retrospective , 
tertiary center 
15 19 n.a. n.a. n.a. n.a. n.a. 
         
Zak 2003 
n = 65 
Retrospective, 
tertiary center 
26 20 45 + + + - 
         
Grassi 2007  
n = 309 
Retrospective, 
tertiary center 
9‡ 20 35 + + + - 






6‡ 12 56 + + + + 
Saurenmann 2007 
n = 1081 
Retrospective, 
tertiary center 
7 13 37 + + + + 
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Bolt 2008† 
n = 265 
Retrospective, 
tertiary center 
5 13 34 + - + - 
         
Reininga 2008 
n = 153 
Retrospective, 
referral center 
7‡ 18 48 + - - - 
         
Nordal 2009 
n = 100 
Prospective cohort, 
population-based 
7 16 n.a + - + - 
         
Skarin 2009 
n = 350 
Retrospective, 
tertiary center 
24 16 58 n.a. n.a. n.a. n.a. 
*References for the studies (39, 45, 127, 129-131, 142, 143, 151-154); JIA = juvenile idiopathic arthritis; Obs = observation; n.a. = not available; ANA = antinuclear    
antibodies. 
†Age at onset of arthritis was significantly lower in the uveitis group in univariate, but not in multivariate analysis.   
‡Followup in years after onset of uveitis.  
1.2 Epidemiology   
Considerable differences in incidence and prevalence of JIA, uveitis and associated 
biomarkers are reported worldwide (155, 156). These diverging numbers may illustrate 
real regional differences, but may also illustrate the difficulties of performing high-
quality epidemiologic studies in JIA, and the validity of some of the data may be 
questioned (157). Epidemiology can be defined as studies of patterns of diseases in 
defined populations to help understand both their causes and the burden they impose 
(158). True differences in incidence of juvenile arthritis between different regions, 
countries and populations can generate hypotheses of etiology and reveal the natural 
history of JIA under current treatment (156).  
 
Study design and methods for patient recruitment obviously have major impact on the 
results (159). Three major points have to be considered; First, uniform classification 
criteria for juvenile arthritis are needed to avoid comparing “apples and pears”. The 
inclusion criteria of JCA requires a longer disease duration than JRA and JIA, and the 
criteria differ in whether the psoriatic and enthesitis-related arthritis are included or not 
(18, 32, 33, 160). Secondly, methods of case identification and ascertainment are 
important (155-157). Disease registries, practioner surveys and hospital populations 
have mostly been used to identify cases. Numbers may be underestimated due to 
undiagnosed cases in the community, or some categories may be overrepresented in 
hospital-based cohorts (155).  Thirdly, there must be a clear definition of the study 
population and the time period. To collect the whole spectrum of a heterogeneous 
disease as JIA, ideally all children in the population should be examined. This is often 
not feasible in a relatively rare disease as JIA. In other approaches studying a given 
population, local hospitals, private specialists and general practitioners must be 
included in addition to referral centers. Otherwise this will influence both findings on 
incidence and prevalence, but also outcome and prognosis because the study group 
may be quite different from the total group of children with JIA. When comparing the 
epidemiologic studies of JIA; crucial questions remain what are due to methodological 
problems, and what are the real geographical and ethnic differences. 
 33 
 
A universal finding is that juvenile arthritis is the most common rheumatic disease of 
childhood (159). Girls are also more frequently affected than boys (26, 125). In most 
population-based studies there is a peak of incidence in early childhood, especially in 
girls 1-3 years of age, while onset in boys is more evenly distributed through 
childhood (102, 122, 125). Reported annual incidence numbers of chronic childhood 
arthritis differ from 1.3 to 22.6 per 100 000 children (102, 161). Incidence figures from 
Europe indicate a north to south gradient even when methodological differences are 
considered (159). The highest annual incidence is reported from Northern Norway, 
and these numbers are confirmed by overlapping confidence intervals in another 
prospective study in the same region (102, 125). An epidemiologic study from the 
Oslo region in 2008 found an annual incidence of 14 per 100 000 and a recent 
prospective study from Catalonia in Spain showed an incidence of 6.9 per 100 000 (24, 
162). 
 
A cross-sectional study based on examination of 12-year old Australian school 
children, showed a surprisingly high prevalence figure of 400 pr 100 000 children for 
juvenile chronic arthritis in 1996 (163). There are wide confidence intervals because 
this calculated prevalence is based on nine identified cases, and the figure thus 
overlaps with a Belgian study with the same design (164). Within the same range is the 
results of a retrospective hospital-based study in Northern Norway showing 164 pr 
100 000 children (102). Three prospective studies in well-defined populations of 
Sweden, Spain and Costa Rica show prevalence of 86 (95% CI 77-96), 40 (95% CI 36-
44) and 31 per 100 000 (95% CI 25-37) and indicate that there are true differences in 
genetic or environmental factors between these populations. 
 
Genetic factors are probably involved in the etiology of JIA. The frequencies of HLA-
B27 among children with JIA are higher in Northern parts of Scandinavia than in other 
studies from Europe and the United States (102, 165). In an Eskimo population 
particularly high incidence of spondyloarthropathy were found in male children, and 
there was also a high prevalence of HLA-B27 in the general population (166, 167). A 
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frequency of 14-17% of HLA-B27 is found in the general population in Northern 
Norway, Northern Sweden and Finland, whereas less than 10% are reported HLA-B27 
positive in southern Norway and other parts of Europe (168). 
 
There are also diverging numbers regarding risk for uveitis among children diagnosed 
with JIA. In the Nordic countries high numbers are reported, showing that 9-24% of 
children with JIA developed uveitis (Table 3) (129, 131, 137). In Costa Rica, 
Singapore and India both uveitis and ANA are rarely found in children with JIA (128, 
169, 170). In multi-ethnic JIA populations, the non-European decent group is shown to 
have less uveitis, fewer children with early-onset ANA positive disease, and more RF 
positive polyarthritis compared to the group with European decent (171). The 
relatively low frequencies of uveitis and positive ANA are suggestive of different 
disease patterns in these populations. This may be an indication of true genetic and 
environmental differences in JIA susceptibility, disease determinants and 
manifestations.   
 
 
1.3 Treatment options in JIA 
At present there are no treatments that can cure JIA; still recent advances in medical 
treatment have changed the goals of treatment over time, with higher expectations for 
achieving inactive disease (46, 172, 173). In a historic perspective there is a long list of 
more or less “useless treatments” that has been given to children with JIA. 
Penicillamine and gold are examples of drugs with numerous side effects and no 
proven efficacy (1). The spontaneous variations in disease activity made it difficult to 
prove efficacy until systematic trials were performed. The old term “slow-acting 
antirheumatic drugs” (SAARD) is indicative of the time and patience needed until 
improvement could be expected (1). Newer medical treatments are effective, but have 
a high cost, and long-term safety is a major concern in children. 
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1.3.1 Current medical treatment  
With the introduction of more effective and targeted antiinflammatory drugs during 
the last decade, three major changes have occurred.  
1. Full remission of the disease has recently been stated as the paramount goal for 
treatment of children with JIA (172). The criteria of remission in JIA, is defined as 
clinically inactive disease either on or off medication (173-175).  
2. There is emerging evidence of a “window of opportunity” when early medical 
treatment can change the disease course in a milder direction in JIA, in the same 
way as previously shown in adults with RA (40, 44, 176-178). Therefore early 
introduction of DMARD is recommended in children with high or moderate 
disease activity and/ or features of poor prognosis (46). 
3. The recommendations towards early treatment have changed the approach from 
starting with the less potent medications to more aggressive treatment upfront (46, 
174, 179). In this way the traditional “pyramid of treatment” has been dismantled 
(180).  
 
The so-called “pediatric rule” implemented by the Food and Drug Administration 
(FDA) and the European Medicine Agency (EMA) stimulate to research on 
therapeutic agents in children, aiming for safer and better use of medicines in children 
(37). Companies that wish to register a new treatment in adults, have to test their 
product in children if there is a pediatric counterpart of the disease (37). Randomized 
controlled trials (RCT) are powerful in testing the effect of new interventions and 
treatments (181). A novel trial design, first used by Lovell et al in the etanercept study, 
solves the ethical dilemma of RCT in potent treatments by offering the active agent to 
all the children, and finding efficacy by withdrawal of the active agent after the first 
treatment effect is achieved (182, 183). During the last decade an increasing number of 
RCT are done in children with JIA. There is an increasing challenge to recruit enough 
children for RCTs on the emerging new biologic treatments. Obviously, international 
collaboration is needed for performing high-quality therapeutic trials in selected 
subsets of JIA. Large pediatric rheumatology networks have been established, such as 
the Pediatric Rheumatology Collaborative Research Group (PRCSG) in the USA, and 
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the Pediatric Rheumatology International Trials Organization (PRINTO) based in 
Europe (2). ACR recommendations of treatment in JIA have been published in 2011 
with a current consensus on medical treatment based on JIA categories and baseline 
predictors of disease course (46). 
 
1.3.1.1 Intraarticular and systemic corticosteroids  
In active arthritis the use of intraarticular corticosteroid joint injections (IACS) is 
recommended and usually very effective, regardless of concomitant therapy and JIA 
category (46). Triamcinolone hexacetonide is a long-acting depot formulation shown 
to be superior to other glucocorticoid formulations in a RCT (184, 185). The efficacy 
and safety is well proven, but a drawback is that most children need sedation or 
general anaesthesia for the procedure (184, 186-189). Although most studies show 
good response, and remission may be sustained, raised CRP levels, negative ANA, and 
ankle injection has been shown to predict synovitis flare (184). Ultrasound guidance 
has been recommended used in the ankle/ tarsal joints and in the hip for correct 
intraarticular administration to improve efficacy (190, 191). To achieve the goal of 
early inactive disease and remission, IACS remains a simple and important treatment 
modality, also in the biologic “era”. 
 
Minimal use of systemic glucocorticoids in children is recommended due to the 
unwanted side-effects such as growth retardation, metabolic alterations and loss of 
bone-mass density (192). Glucocorticoids can be useful as a “bridging” therapy until 
an effect of slower acting DMARD is seen. In systemic JIA with active fever, the 
standard treatment has been systemic glucocorticoids, even though there is a recent 
report on alternative upfront treatment with IL-1 blocking agents (193). Recent 
research indicates a favourable effect of the anti-diabetic drug metformin in reducing 
the metabolic side effects of glucocorticoids (194, 195). 
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1.3.1.2 Nonsteroidal antiinflammatory drugs  
Even though IACS and early DMARD currently are introduced early, NSAID has 
been the most frequently used medication in JIA for decades (46, 196, 197). NSAID is 
still the analgesic drug of choice in JIA, but other treatments are recommended for 
long-term antiinflammatory effects (46). The frequency of gastrointestinal and other 
side effects, and also drug discontinuation due to toxicity is not significantly different 
from DMARD (198).  
 
1.3.1.3 Methotrexate  
Methotrexate (MTX) is the cornerstone of long-term disease-modifying therapy in JIA 
(46). MTX together with IACS is recommended as the initial treatment in high and 
moderate disease activity, with the aim of inducing early inactive disease and 
remission (46). MTX can be taken orally, but the parenteral route ensures better 
absorption (196). Improvement cannot be expected until 6-12 weeks after starting 
treatment, and efficacy has been shown in several trials (199, 200). PRINTO has 
conducted a large scale RCT on methotrexate dosing in JIA, concluding that a medium 
dose of 15 mg MTX/ m2 is as effective as higher doses (201). A major limitation of 
concern is liver toxicity and gastro-intestinal side effects (198). A small study on 
interaction between NSAID and MTX indicate that side effects usually attributed to 
MTX, may be caused by increased levels of concomitant NSAID (202). Folic acid 
supplementation may reduce the gastrointestinal side effects (203). 
 
1.3.1.4 Other DMARD 
Other DMARD such as leflunomide, sulphasalazine, hydroxychloroquine and 
cyclosporine are sometimes used in the treatment of JIA (46). There are some evidence 
for superior effect of the combination therapy of methotrexate, sulphasalazine and 
hydroxychloroquine to methotrexate alone in early polyarticular JIA (204). 
Leflunomide and sulphasalazine are both shown to have effect in monotherapy for 
selected categories, but the clinical improvement seems to be inferior to methotrexate 
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(176, 205, 206). A disease-modifying effect of cyclosporine or hydroxychloroquine 
has not been proven, but the latter has a metabolic effect in lowering blood glucose, 
low density lipoprotein (LDL) and cholesterol levels, and can diminish the increased 
cardiovascular risk inflicted by oral corticosteroids (205, 207).  
 
1.3.1.5 Biologic treatment  
Advances in the understanding of the immune system have led to development of new 
targeted drugs that interfere with key cytokines of inflammation (208). These drugs are 
called biologic agents in contrast to methotrexate and the other synthetic DMARDs. 
Etanercept, infliximab and adalimumab are potent TNF-blocking agents all shown to 
be effective and generally well-tolerated in JIA (183, 209-211). Only etanercept and 
adalimumab are licensed for use in children with JIA, while adalimumab and 
infliximab has the advantage of being effective both for the arthritis and for JIA-
associated uveitis (212-214). Another biological agent is abatacept, targeting CTLA-4, 
shown efficacious for polyarticular course-JIA in a RCT (215). For the systemic 
category of JIA the interleukin-blocking agents anakinra (IL-1) and tocilizumab (IL-6) 
are shown to have a profound effect, and may be used as first-line disease-modifying 
treatment (193, 216-218). Further biologic agents are available, some are currently 
being studied for use in children and new drugs are steadily emerging (219). 
 
1.3.1.6 Medical treatment of uveitis 
Systemic medical treatment is indicated if topical corticoid treatment cannot control 
the uveitis (220). Local corticosteroid injections may be used (220). Methotrexate is 
reported effective in an observational study. It is the most commonly used systemic 
antiinflammatory drug, although no RCT has been performed (221). Mycophenolate 
mofetil and cyclosporine A have also been used (220). Among the biologic agents, 
infliximab, adalimumab, and rituximab are in several case series shown effective 
against uveitis (148, 213, 214). 
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1.3.2 Other treatment options 
Although there have been great advances in medical treatment, the followup of a child 
with JIA is still considered to be a multi-disciplinary task (37). The specialized multi-
disciplinary team has an important role in assessing the individual needs of the child 
and family, and to facilitate that these needs are met locally in school, kindergarten 
and in the primary health care (192). 
 
There has been a dramatic shift in attitude regarding physical activity for children with 
chronic arthritis (222). Recent advances in treatment have led to less disability, and 
therefore less need for mechanical aids, splints and surgery. In earlier days bed rest 
and immobilization in general or as a consequence of frequent use of orthoses, casts 
and splints, was widely advocated for children with JIA (223). Replacing the previous 
traditions of giving advice to avoid many activities, all physical activity is now 
generally recommended (222, 224). There is some evidence that structured aerobic and 
neuromuscular training may improve exercise capacity, functional performance, and 
quality of life in children and adolescents with JIA (222, 225). Recent research also 
points to an anti-inflammatory effect of exercise that may be mediated by muscle-
derived cytokines (226, 227). Different physiotherapeutic approaches are used in 
different centers around the world (228). A RCT could not show any beneficial effect 
of hydrotherapy compared to land-based physiotherapy, but in both treatment groups 
there was an improvement in the core variables of JIA, and also improvement in 
HRQoL and cardiovascular fitness (229). A time-limited, intensive training period of 
physiotherapy may facilitate participation in ordinary activities as sports and physical 
education in school. The pediatric nurse has an important role giving information 
regarding vaccines and teaching safe administration of injections and other 
medications. An occupational therapist with knowledge on hand function and helping 
aids, and a social councilor are also important members of the multidisciplinary team. 
The pediatric rheumatologist is usually the coordinator of the team, which may involve 
other professionals as an ophthalmologist, orthopedic technician, orthopedic surgeon, 




JIA may have considerable impact on growth and development, physical and 
psychosocial functioning. There is a wide range of potential consequences, and 
therefore no single measure of outcome. Knowledge on the long-term outcome of JIA 
is important to guide treatment, for information to the individual child and family, and 
for the society in providing health services (156).  
 
Outcome can be defined as consequences of the disease process over time. Strictly 
speaking, outcome can be described precisely only at the end of the disease process, 
still both short- and long-term studies provide valuable information. A conceptual 
framework of the disease process, prognostic and interacting factors, and outcome is 
suggested in figure 2. Robust definitions of disease activity, remission and other 






















* ANA = antinuclear antibodies; AHA = antihistone antibodies; JADAS = juvenile arthritis disease activity 
score; Physician GA = physicians global assessment of disease severity; Child/par GA = child/parent global 
assessment of overall well-being; Pain VAS = pain visual analogue scale; CHAQ = childhood health assessment 




Figure 2.  A framework for prognostic factors and outcome in the disease process of JIA. The 
main prognostic markers and outcome measures used in the present study are underlined. 
Modified from WHO framework for consequences of disease in the International 
Classification of Functioning, Disabilities and Health (226), Spector and Hochberg (232), 
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Outcome Prognostic factors 
Interacting factors 
Infectious agents, health care access, treatment, mental health, coping, family support 
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1.4.1 Current knowledge on outcome in JIA  
A common belief as late as in the 1990’s was that most children with JIA would 
achieve permanent remission before adult age (208). This view has changed because 
several recent studies have demonstrated ongoing or cyclic disease activity into 
adulthood for about two thirds of the children (42, 45, 63, 236, 237). Outcome studies 
show inconsistent and conflicting results, and reflect methodological problems such as 
study design, study population and method of case accrual (156). In most studies the 
number of patients in each category is low, so the category-specific results must be 
interpreted with caution. Hospital-based studies from tertiary pediatric or adult 
rheumatology centers will evaluate a selected cohort with an outcome that may differ 
from population-based studies. On the other hand, cross-sectional studies miss 
fluctuations in disease activity over time, and cannot measure sustained clinical 
remission off treatment (42). Disease activity should therefore be assessed over time to 
avoid underestimation of duration and chronicity of the disease. 
 
Even if ongoing disease is found in a majority of children with JIA, the disease activity 
seems generally low (39, 63, 237). Many children do not have joints with active 
inflammation or restricted movements at followup in long-term studies, probably 
reflecting that therapeutic interventions are promptly started at disease flares (44, 237).  
 
Physical functioning is in average lower than in healthy controls, but the difference is 
small in most studies, assessed by CHAQ and CHQ (39, 237). Disease-related pain is 
reported present in 40-86% of the patients on followup, not necessarily proportional to 
other measures of disease activity (238, 239). Psychosocial functioning is in the 
normal range for most patients with JIA, although some conflicting data exist (238-
240). School attendance and participation in social activities are often influenced by 
the disease, but the majority of long-term followup shows that educational levels and 
spousal relationships are similar to healthy controls (39, 45, 240). In some studies 
there is a lower employment rate of adults with juvenile onset arthritis compared to the 
background population (240, 241). 
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Remission rates in recent studies range from 33 – 61%, and are summarized in table 4. 
These rates are however assessed at the final study visit, reporting the disease state of 
the last 1-2 years depending on which criteria of remission is used. When the whole 
disease course is assessed, Wallace et al found that only 36% of remission episodes 
were sustained for 2 years and only 6% for 5 years (42). In a similar way Lurati et al 
report sustained remission for 2 years in only 25% of 761 Italian children in a 7.6 year 
followup (236). Both these studies from tertiary referral-centers are retrospective, and 
there is a need for population-based prospective studies to confirm this high grade of 
chronicity in JIA. 
 
A Steinbrocker functional class III and IV indicate significant physical disability. 
Approximately 10% or less of the patients with JIA belongs to these functional classes, 
even in recently published studies that assess patients after many years of disease (44, 
237, 242). Permanent damage has also been assessed by juvenile arthritis damage 
index (JADI) from different parts of the world, showing diverging results (237, 243-
245). Visual impairment is a significant problem with severe consequences for 
children with difficult-to-treat JIA-associated uveitis (136). 
 
There are other long-term consequences of JIA beyond functional disability and joint 
damage. In adults with rheumatic arthritis there is a marked increase in cardiovascular 
disease (CVD) risk associated with chronic inflammation, comparable to the increased 
risk of CVD in diabetes mellitus (246). In children with JIA there is so far not shown 
increased risk of CVD, but there are indications of blood wessel endothelial 
dysfunction, that may be attributed to inflammation or medications (247). A small but 
significant increased risk of cancer has been found in children with JIA diagnosed 
after the mid-eighties (248). A large international long-term surveillance study is 
started to clarify whether this is related to the disease per se or to the treatment with 
methotrexate, biologic or other antiinflammatory agents (249). The mortality rate in 
JIA has been slightly raised compared to the background population in some studies, 
but a recent report from the USA showed no increased mortality in JIA (250).     
Table 4. Recent outcome studies in juvenile arthritis.* 
Author, year 
(n) 















Gäre 1995  




7 0.19/60 49/-/- 61‡ -/ 5 JCA 
Zak 2000  




26 - - 73 -/11 JCA 
Arguedas 2002 




4 - 49/25/25 51§ -/- JCA 
        
Minden 2002 




and tertiary center 
 
16 0.22/39 -/-/- 40 -/10 JCA 
Oen 2002 





10 -/55 -/21/- 39 -/3 JRA 
Packham 2002 






28 -/43** >80/36/- - -/37 JIA 
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Fantini 2002  




10 - -/-/- 33 -/- JCA 
Flato 2003 
n = 268 
 
Case-control 
Tertiary center  
15 -/36 -/-/- 50 -/- JRA 
Foster 2003 




21 1.1/- 68/28/15 61§ -/- JIA 
Arkela-
Kautiainen 2005 
n = 123 
 
Retrospective 
Tertiary center  
16 -/- - /- /58 37 -/- JIA 
Solari 2008 




7 0/49 77/-/53 22§ >34/4 JIA 
Nordal 2011  




8 0/32 35/31/23 42 23/- JIA 
*References for the studies (39, 47, 49, 128, 151, 237, 240, 242, 251-253); CHAQ = Childhood health assessment questionnaire; DMARD = Disease-modifying   
antirheumatic drugs; MTX = methotrexate; JADI = Juvenile arthritis damage index; - = not available; JCA = Juvenile chronic arthritis; JRA = Juvenile rheumatic           
arthritis; JIA = Juvenile idiopathic arthritis. 
† The EULAR and several different study-specific definitions of remission are used. In the studies of Solari, and Nordal the Wallace criteria of remission are used (175). 
‡ Extrapolated remission rate from the examined cohort to the original population-based cohort, other outcomes are from the examined cohort. 
§ Inactive disease and remission, the EULAR and several different definitions of inactive disease and remission are used.  
** Percentage of patients with CHAQ >1.5. 
 
1.4.2 Validated outcome measures 
Disease-related outcome measures are necessary for reliable and valid evaluation of 
disease activity and outcome. Validated tools for assessment of self-reported health and 
functional status, remission and damage are essential to describe the effect of treatment 
in trials, and the disease course and outcome in epidemiologic studies (Table 5) (254).  
 
1.4.2.1 Disease activity measures  
Simple measures of disease activity are; the number of inflamed joints, tender joints, 
joints with restricted movement, inflammatory markers and visual analogue scales of 
pain, and global assessment of disease severity. Among these physicians global 
assessment of disease activity and active arthritis joint counts show high correlation to 
other measures of disease activity and has a high responsiveness to change (255, 256). A 
composite disease activity score combining four of these simple measures was recently 
developed and validated (257). Juvenile Arthritis Disease Activity Score includes the 
following measures; (1) number of joints with active arthritis assessed in 10, 27 or 71 
joints, (2) parent/patient’s global assessment of well-being, (3) physician’s global 
assessment of disease activity, and (4) ESR. The sum of these four components yields a 
number on a continuous scale to quantify disease activity. The ACR pediatric response 
criteria (ACRpedi30, 50, 70) are standardized treatment response measures defining 
clinical improvement (258). This core set of six variables include the CHAQ score and 
the number of joints with restricted movements, in addition to the variables included in 
the JADAS. The score is a calculation of improvement in these variables over time. An 
advantage of JADAS is the ability to measure disease activity in individuals or groups 
of patients at a single visit. Both JADAS and ACRpedi are validated for use in JIA in 




1.4.2.2 Patient-reported outcome 
Questionnaires that encompass broad aspects of functioning, pain and health-related 
quality of life (HRQoL) are useful in daily clinical care (259). A generally accepted 
definition of Health Related Quality of Life (HRQOL) is the patient’s subjective 
perception of the impact of his disease and its treatment on daily life; physical, 
psychological, social functioning and well-being, while QOL is usually described as an 
overall assessment of well-being (255). In children self-reported measures is filled in by 
their parents/ proxies until the child is able to report themselves. This is a practical, 
although not perfect way of reporting, because discordance between proxy-reported and 
observed assessment of functional ability is found (261). Questionnaires can be filled 
out in the waiting room before the visit. This allows the patient to consider the impact of 
disease on their daily life recently, and at the visit the physician can get an impression of 
disease activity and impact by a quick glance. 
 
To secure the perspective of the child and the parents, Child Health Assessment 
Questionnaire (CHAQ)) and Child Health Questionnaire (CHQ) are translated and 
validated in many languages, including Norwegian (262, 263). CHAQ measures 
physical functioning in 30 items divided into 8 domains (dressing, arising, eating, 
walking, hygiene, reach, grip, activities), including registration of aids and devices, and 
help from other persons for physical functioning. It also includes two visual analogue 
scales on pain and overall well-being. CHAQ is the most extensively used patient-
reported outcome measure in JIA, has a high reliability, but only a moderate correlation 
with other disease activity indices, and shows a low responsiveness to change. A ceiling 
effect may be a problem, because most children with JIA report low levels of disability 
according to the CHAQ (263). The CHQ is a family of generic quality of life 
instruments measuring 14 physical and psychosocial domains. These cover broad 
aspects of daily functioning and the domains can be combined in a psychosocial and 





1.4.2.3 Inactive disease and remission 
Several different definitions of inactive disease and remission in chronic childhood 
arthritis have been used. ACR provisional criteria for inactive disease and remission are 
recently published by Wallace et al in order to standardize this important outcome 
measure (Table 5) (173).  
 
 
Table 5. American College of Rheumatology provisional criteria for inactive disease and the 
preliminary criteria for clinical remission of juvenile idiopathic arthritis (JIA).  
 
Inactive disease:* 
No joints with active arthritis 
No fever, rash, serositis, splenomegaly, or generalized lymphadenopathy attributable to JIA 
No active uveitis as defined by the SUN Working Group† 
ESR or CRP level within normal limits or, if elevated, not attributable to JIA‡ 
Physician’s global assessment of disease activity score = best possible on the scale used 
Duration of morning stiffness of <15 minutes 
 
 
Clinical remission: Two types of clinical remission are proposed§ 
Clinical remission on medication. The criteria for inactive disease must be met for a 
minimum of 6 continuous months while the patient is on medication in order for the patient to 
be considered to be in a state of clinical remission on medication 
Clinical remission off medication. The criteria for inactive disease must be met for a 
minimum of 12 continuous months while off all anti-arthritis and anti-uveitis medications in 
order for the patient to be considered to be in a state of clinical remission off medication 
 
*All criteria must be met.  
†The Standardization of Uveitis Nomenclature (SUN) Working Group defines inactive anterior uveitis as “grade 
zero cells,” indicating <1 cell in field sizes of 1 mm by a 1-mm slit beam. 
‡ESR = erythrocyte sedimentation rate; CRP = C-reactive protein.  
§ Based on the previously published preliminary criteria of remission and inactive disease in select categories of 
JIA (175). Adapted from Wallace et al in J Rheumatol 2004 and Wallace et al in Arthritis Care Res 2011 (173, 
175).  
  
1.4.2.4 Other outcome measures  
Steinbrocker functional class has been used for more than six decades to describe 
function and damage in rheumatic diseases (265). Due to significantly improved 
outcome during the last decades, this measure is less used nowadays. Juvenile Arthritis 
Damage Index (JADI) is a newer validated clinical tool for physicians to assess 
permanent articular and extraarticular damage in JIA (245).  
 
Bone erosions are a sign of joint damage caused by the disease, but even severe bony 
destruction may to some degree be reversible in children. Several radiological scores 
have been developed for JIA to standardize descriptions of bony erosions, destruction 
and growth disturbances (266-268). Recently, a standardized score for magnetic 
resonance imaging (MRI) in children with JIA is also proposed, but more knowledge 
on normal MRI of the growing skeleton is clearly needed (269-271).     
 
1.4.2.5 Developing validated outcome measures 
Outcome tools have been derived in many different ways. When there is clinical need 
for a precise measure, creativity methods may be used (254). In a structured form of 
brainstorming, experts in the field generate a wide range of answers to the topic 
discussed, and then the variables are narrowed down to the most important items. 
Examples of this process are the Delphi and the nominal group technique (254). Such 
proposed consensus criteria, followed by several validation studies, have resulted in 
the provisional ACR criteria for inactive disease in JIA (173, 175, 272). Some 
measures have been adapted from adult rheumatology for use in children, i.e. the 
CHAQ is a children’s version of HAQ developed for rheumatoid arthritis (233, 273).  
 
A thorough testing for reliability and validity is necessary before an outcome measure 
can be trusted. Face validity is an important aspect describing that the outcome 
measure is feasible and user-friendly. Content, criterion and construct validity must be 
verified, showing that the tool measures essential items, can predict certain outcomes, 
and measures what it is intended to measure. Discriminative ability ensures that the 
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measure is able to detect clinically important differences, for example between healthy 
children versus children with JIA or low versus high disease activity (254). The tool 
should also be sensitive to measure change over time, for example before and after an 
intervention, and test-retest reliability should be present. 








Disease Activity    
Child/parent global assessment of  
overall well-being (VAS 0-10)  
PR Generic Overall well-being 
Physician global assessment of  
disease severity (VAS 0-10) 
Physician Generic Disease severity 
Pain (VAS 0-10) PR Generic Pain  
ACR Pedi30, 50, 70 = ACR pediatric 
measures of improvement criteria 
Physician Disease-specific Composite  
improvement  
JADAS = Juvenile arthritis disease  
activity score 
PR/ physician Disease-specific Composite disease  
activity  
    
Function and HRQoL    
CHAQ = Childhood health  
assessment questionnaire 
PR Disease-specific Physical function 
CHQ = Child  
health questionnaire  
PR Generic Physical function,  
Psychosocial function 
JAQQ = Juvenile arthritis  
quality of life questionnaire 
PR Disease-specific Physical function,  
psychosocial function, 
and general symptoms 
Steinbrocker  
functional class (I-IV) 
Physician Disease-specific Physical function 
JAMAR = Juvenile arthritis 
multidimensional assessment report 
PR Disease-specific Physical function,  
psychosocial function, 
HRQoL, compliance, 
side effects, and  
general symptoms  
JAFAR = Juvenile arthritis  
functional assessment report  
PR Disease-specific Physical function 
CHAIMS = Childhood Arthritis 
Impact Measurement Scales  
PR Disease-specific Physical function  
and pain 
    
Damage    
JADI =  
Juvenile arthritis damage index 
Physician Disease-specific Articular and  
extraarticular damage 
    
 Radiology scores Physician Disease-specific Bony destruction,  
growth disturbance 
*VAS = Visual analogue scale; PR = Patient/parent-reported; ACR = American College of Rheumatology;                                  
HRQoL = Health-related quality of life; references for the outcome measures (245, 257-259, 263-268, 273-278) 
 
1.4.3 Contextual factors in outcome 
There are numerous factors in addition to the disease itself that influence outcome. 
Access to adequate care for children with chronic diseases is a global challenge. A 
goal must be that adequate health care and treatment is available to all children also in 
less privileged countries. According to the UN convention on rights of the child, 
children has the right “to the enjoyment of the highest attainable standard of health and 
to facilities for the treatment of illness and rehabilitation of health” (273) . Late access 
and poor health care for less privileged groups is a political issue, when there are 
short-comings of governmental health care. Children with JIA in the USA are less 
likely to have the recommended eye screening if they are not covered by a private 
insurance (280). Biologic agents for control of arthritis and uveitis are expensive and 
therefore not available to many children worldwide. 
 
A prolonged interval from onset of symptoms to the diagnosis is established and 
treatment started, may adversely affect clinical outcome. Longstanding arthritis before 
joint injection is performed is shown to increase the risk of leg length discrepancy, 
muscle wasting or functional disability (281). Longer time interval until start of 
DMARD treatment is a predictor of lower treatment response (44, 177). Health care 
workers should be trained in musculoskeletal examination in order to recognize signs 
of rheumatic disease in children and avoid prolonged delay. A statement on standards 
of care for JIA is recently developed by British pediatric rheumatologists to ensure 
adequate health care for children with JIA (172, 230, 282). 
 
Compliance to prescribed treatment is an under-recognized problem in medicine. 
Adherence to medical regimens may influence the outcome in JIA. Nausea and other 
gastrointestinal side effects of methotrexate are common, and often increase over time 
(198). This problem is increasingly recognized and non-medical techniques as 
cognitive therapy and hypnosis is described to be helpful (283). Adolescence is a 
particularly vulnerable age, where the motivation to regular intake of medicines is 
variable. The transition from pediatric to adult health care can be problematic, and the 
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challenge is to provide developmentally appropriate and uninterrupted health care 
(284-286). Knowledge on the disease, self-management strategies and meaningful 
social support was rated by young people to be important factors in this period of 
transition (287). Young people should be given the chance to express their views and 
be seen without their parents at visits (284). Continuity in health personnel, 
individualized timing of information and transition, and increasing self-advocacy over 
several years are important elements of a successful transition process (288, 289). A 
structured and evidence-based transitional care program is shown to increase health-
related quality of life in adolescents moving on from pediatric to adult care (290). 
 
 
1.5 Study design in JIA research 
Historically, knowledge in pediatric rheumatology was based on case reports, case 
series and hospital-based retrospective cohorts. In spite of numerous studies reporting 
incidence, course and outcome in JIA, results are difficult to compare, and evidence-
based knowledge is still sparse. Selection bias is a common problem, limiting 
generalizability of the findings. Important recent contributions come from population-
based cohorts and registries, cross-sectional studies, and also randomized controlled 
trials (181). Case reports, case series, case-control and prospective cohort studies may 
all play important hypothesis-generating roles, while experimental studies are 
considered gold-standard of elucidating causal mechanisms (158). There is increasing 
attention to the need for translational research, moving scientific results from basic 
science into better clinical outcomes (89, 291). Epidemiologic research in JIA is an 
important source for new hypotheses on etiology, clearer definitions and classification 
of categories, disease course and outcome (159). RCT and metaanalyses of RCT are 
considered to give the most important contribution to evidence-based medicine (Figure 
2). However, many important research questions cannot be answered by a RCT. 
Criticism have been raised that the “hierarchy of evidence” is a narrow idea that only 
applies to therapeutic evaluation, particularly of drugs (158). Other designs are more 
important in understanding causality, and the spectrum and burden of the disease. 
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Therapeutic trials on treatment are based on knowledge from epidemiologic, basic and 
translational research. A wide range of research methods are needed to gain more 





Figure 3. “Dismantling the pyramid”; from a hierarchical to a circular model of 
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2 AIMS OF THE STUDY 
 
 
To study disease activity and outcome in JIA in a prospectively collected cohort of 
children included shortly after diagnosis in defined geographical areas of the Nordic 
countries by;  
I. Assessing disease characteristics, course and long-term outcome including 
changing JIA categories, medical treatment, damage, and remission status in a 
population-based setting.  
 
II. Evaluating the newly developed disease activity score (JADAS) by; 
a. Comparing the JADAS based on CRP to JADAS based on ESR.   
b. Testing JADAS in a population-based setting.   
 
III. Evaluating biomarkers and clinical risk factors for development of chronic       
uveitis; antihistone antibodies, ANA by immunofluoresence and ELISA analyses, 





3 MATERIAL AND METHODS 
The study was initiated and designed by The Nordic Study group of Pediatric 
Rheumatology (NoSPeR), a researcher-initiated group of experienced pediatric 
rheumatologists. Members of the group have initiated and conducted other large scale 
prospective epidemiologic studies on incidence and outcome in JIA in southern 
Sweden and in Costa Rica (47, 122, 124, 125, 128, 137, 292). The Nordic JIA study 
has previously been the basis of a thesis of medicine (PhD) by Dr. Lillemor Berntson, 
Göteborg in 2003, and also resulted in several publications in international journals of 
rheumatology (35, 62, 125, 160, 256, 293). Meetings in the steering group of NoSPeR 
have been held twice yearly since 1995 for planning, initiating and conducting the 
study. Protocol details and definitions have been discussed and clarified throughout the 
study period. In case of missing or conflicting information, each center has been asked 
for clarifications repeatedly during the study period.  
 
 
3.1 Study design   
The Nordic JIA study is a prospective, multi-center cohort study of juvenile idiopathic 
arthritis in defined geographical areas in Denmark, Finland, Norway and Sweden.  
 
 
3.2 Inclusion criteria 
All children with a new diagnosis of JIA according to the ILAR criteria within the 
study period and living in the study areas at disease onset were included. Study areas 
and inclusion periods are described in table 7. The minimum requirement for 
continued inclusion in the followup study was 2 registered visits, including the 
baseline visit and a followup visit more than 7 years after disease onset for study I, and 
a followup visit more than 3 years after disease onset for study III. All study visits 
with JADAS variables recorded in children included during an extended study period 
(Table 7), were analyzed in study II. During the study period, pediatric 
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rheumatologists from 12 participating centers registered all consecutive new patients 
with JIA diagnosed according to the ILAR criteria. With the aim of making the study 
as close to population-based as possible, letters were repeatedly sent to the primary 
health care and all orthopedic, pediatric, and rheumatology specialists in the catchment 
areas during the inclusion period, requesting referral of potentially eligible patients. To 
our knowledge only 3 of all eligible patients did not wish to take part in the study. In 
the Nordic countries, all visits to primary care physicians and public hospitals are 
mostly free of charge for children under 16 years of age, and the health care systems 
include regular visits at a child health center for preschool children. The health care 




Table 7. Inclusion periods of the different studies in geographical areas of the Nordic juvenile idiopathic arthritis  
   cohort included in the thesis. 
 









Denmark, East 01.01.1997- 31.12.1999 01.01.1997- 30.06.2001 - 
Denmark, Århus 01.07.1997- 31.12.1998 01.01.1997- 31.12.1998 - 
Finland 01.07.1997- 30.06.2000 01.01.1997- 30.06.2001 - 
Norway 01.01.1997- 30.06.2000 01.01.1997- 30.06.2000 01.01.1997- 31.12.2002 
Sweden 01.01.1997- 31.12.1999 01.01.1997- 31.12.1999 - 
 
  
3.1 Patients and settings  
The study areas are shown in figure 4. The centers and corresponding areas taking part 
in the study were those that had a tradition of diagnosing and treating all new cases of 
JIA in their catchment areas. The incidence of JIA in the study area in 1997- 1998 was  
15 per 100.000 children/ year (range 9 - 23 in different areas) as previously reported 
(11). The estimated population at risk in the study areas were 1 413 738 children aged 
<16 years in 1999 (11). Iceland, the fifth Nordic country, was part of the initial 
incidence study, but has not taken part in the present followup study. The inclusion 
period for Study I was the period that all centers put in maximum efforts to include all 
eligible children from their area (Table 7). In Study II the aim was to validate JADAS, 
and we decided to include all visits with all JADAS items available in the study 
database, extending the inclusion period to include some patients not included in study 
I (38 of the 389 patients). The overlap between the study cohorts of studies I - III are 
shown in Figure 5. The followup period of study I and II was up to 12 years. In Study 
III the Norwegian children from Troms, Finnmark, Nord-Trøndelag, Sør-Trøndelag 
and Møre- og Romsdal regions were included from the study centers of Tromsø and 
Trondheim (Figure 4, red areas). Study III was started as a pilot study of all 
Norwegian children that were registered in the Nordic JIA database, and the data and 
laboratory analyses were performed before the 8-year followup was finalized. A 
majority of the patients in study I were also part of study II and III. The followup 
period of study III was up to 11 years. The numbers of patients lost to followup and 
time points of dropping out of the followup group are shown in the flowchart in figure 
6 and figure 7. Among the 60 patients lost to followup, 17 had moved, 12 did not wish 
to participate in further followup, and the rest gave no response or “unknown reason” 
was noted. Comparing the followup group and the 12.0% lost to followup, there were 
no significant differences in baseline characteristics with respect to number of active 
joints during the first six months after onset, CHAQ and JADAS27 score, or 
proportion with oligoarticular subtype. However, higher median age at onset and 
presence of RF, lower median ESR, CRP and presence of ANA, were found in the 






Figure 4. Map of the Nordic countries showing the geographical areas of the Nordic JIA 


















Figure 5. Diagram showing the partially overlapping study cohorts of the Nordic JIA 
database, the population-based Nordic JIA cohort, the JADAS validation study, and the 
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Figure 6. Flow chart of the Nordic JIA study showing the proportion of children lost to 





≥7 year followup JIA 
n = 440 
F = 291  M = 149 
Lost to followup 
n = 60 
F = 41  M = 19 
 
Included at baseline 
n = 500 
F= 332  M= 168 
≥3 y followup JIA 
n = 476 
F=315  M=161 
≥5 y followup JIA 
n = 453 
F= 300  M= 153 
≥1 y followup JIA 
n = 493 
F= 327  M= 166 
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Figure 7. Diagram of number of participants and children lost to followup during the study 
period in the different countries in the Nordic JIA study. 
 
Table 8. Clinical characteristics of participants in the Nordic juvenile idiopathic arthritis (JIA) cohort at the first study visit, median 
seven months after disease onset 
 Total Followup participants  Participants lost to followup P* 
 No. No. (%) No. No. (%) No. No. (%)  
Female gender 500 332 (66.4) 440 291 (66.1) 60 41 (68.3) NS 
Oligoarticular† 500 262 (52.4) 440 225 (51.1) 60 37 (61.7) NS 
ANA positive‡ 449 113 (25.2) 391 107 (27.4) 58 6 (10.3) 0.005 
RF-positive‡ 439 15 (3.4) 389 10 (2.6) 50 5 (10.0) 0.006 
HLA-B27 positive 431 91 (21.1) 385 83 (21.6) 46 8 (17.4) NS 
  Median (IQR)  Median (IQR)  Median (IQR)  
Age at onset (years)  500 5.9 (2.7-10.0) 440 5.5 (2.5-9.7) 60 8.8 (4.7-12.0) 0.0006 
Active joints first six months 453 3 (1-6) 399 3 (1-6) 54 2 (1-5) NS 
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CRP§ 395 0 (0-10) 354 0 (0-10) 41 0 (0-0) NS 
CRP maximum value§  368 13 (0-33) 332 14 (0-35) 36 0 (0-18) 0.023 
ESR§ 399 13 (8-27) 358 14 (8-28) 41 10 (5-15) 0.025 
ESR maximum value§ 368 33 (15-35) 333 35 (16-56) 35 18 (10-36) 0.014 
Parent/pat global assessment§ 299 1.0 (0.2-3.0) 271 1.0 (0.2-3.0) 28 1.0 (0.0-2.3) NS 
Physician global assessment§ 278 1.0 (0.5-3.0) 248 1.0 (0.5-3.0) 30 1.0 (0.9-2.0) NS 
CHAQ§ 309 0.3 (0.0-0.9) 278 0.3 (0.0-1.0) 31 0.1 (0.0-0.4) NS 
JADAS27 220 5.0 (2.0-10.2) 197 5.0 (2.0-10.5) 23 4.4 (2.0-8.0) NS 
* Chi-square test for dichotomous outcomes and Mann-Whitney U test for comparison of median values. P values are obtained comparing the followup study group with 
participants lost to followup. NS = not significant. 
† Oligoarticular JIA six months after onset of disease, according to the International League of Associations for Rheumatology (ILAR) classification criteria (5). 
‡ ANA = antinuclear antibodies and RF = rheumatoid factor; two positive tests taken >three months apart in participants with one or more tests taken. 
§ Disease activity characteristics; CRP = C-reactive protein and ESR = erythrocyte sedimentation rate, at six months and maximum value reported during the first six 
months; Parent/pat global assessment = parent’s (child <9 years) / patient’s (child ≥9 years) global assessment of overall well-being 10-cm visual analogue scale (VAS) 
(range 0-10); Physician global assessment = Physician’s global assessment of overall disease activity 10-cm VAS (range 0-10); CHAQ = Child health assessment 
questionnaire; JADAS27 = Juvenile arthritis disease activity score based on 27 joints (range 0-57). 
3.2 Data collection 
Family histories, extensive clinical data including complete joint counts, 
ophthalmologic status, medications used, patient/parent-completed health assessment 
measures, and results of blood tests were registered per protocol in a database at all 
study visits. A study visit was planned every 6 months during the first year after 
disease onset and then every 1-2 years during the observation period. Fewer visits 
were registered mainly in Finland and Denmark, and totally a mean of 5 visits were 
registered per participant. A minimum of two registered visits were required for 
staying included in the study. At the final study visit of study I, 8 years after disease 
onset, extended information was collected, including an update on family history. For 
the final visit of study I, participating patients received a letter of invitation followed 
by a reminding letter; patients who did not respond were contacted by telephone and 
asked to participate in a visit. In the few cases in which a final study visit was not 
possible to obtain, the patients were asked to participate in a telephone interview. This 
standardized telephone interview contained all information that otherwise, per 
protocol, was collected during visits. This included the patient’s own description of 
involved and restricted joints, presence of uveitis and systemic features. The patients 
were asked if they were willing to fill in and return relevant questionnaires sent by 
ordinary mail. In all participating children the JIA categories were determined 
according to the ILAR criteria (18), based on all available information that was 
registered at each visit during the study period. Uveitis was defined as present, when 
the ophthalmologist prescribed treatment of uveitis. The uveitis was described in terms 
of presence of symptoms, duration, and course of uveitis in the database, and 
retrospectively classified according  to the recommendations by the Standardization of 
Uveitis Nomenclature (SUN) working group (132). Uveitis was then defined as 
“acute,” symptomatic with acute onset and limited duration, or “chronic” insidious 
onset, mainly asymptomatic with chronic recurrent or persistent course. The Juvenile 
Arthritis Damage Index (JADI) (245) was scored by the pediatric rheumatologist; 
articular damage was scored on a scale in which 0 = no damage and 72 = maximum 
damage, extraarticular damage was scored on a scale in which 0 = no damage and 17 = 
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maximum damage, and global damage were scored on a 10-cm VAS in which 0 = no 
damage and 10 = maximum damage.  
 
3.2.1 Patient/parent-reported measures  
Questionnaires on self-reported health-related quality of life were registered; the Child  
Health Questionnaire (CHQ) was used for patients younger than 18 years (259;283-
286), and the HAQ (233) (0 = best and 3 = worst) and Short Form 36 health survey 
(SF-36) (294) were used for patients older than 18 years. The CHQ and the SF-36 are 
generic instruments comprising subscales on aspects of physical, emotional, and social 
health, yielding a physical score and a psychosocial summary score, with higher scores 
indicating better health (range 0- 100, mean SD 50 +/- 10) (264). Scores for the 
Childhood Health Assessment Questionnaire (C-HAQ; 0 = best and 3 = worst) (16–
20) and scores on a 10-cm visual analog scale (VAS) for pain (0 = no pain and 10 = 
worst pain) and overall well-being (global health; 0 = best and 10 = poorest) were 
provided by patients who were older than 9 years and by the parents of younger 
patients. Global disease activity was assessed by the physicians, using a VAS (0 = no 
activity and 10 = maximum activity).  
 
3.2.2 Laboratory methods  
C-reactive protein was measured with immunoassays, with upper normal values 
ranging from 3-10 mg/liter; in the study protocol, the cut-off value for the whole 
population was set to <10 mg/liter. HLA-B27 antigens were analyzed. RF status was 
determined by ELISA (Denmark), nephelometry (Norway and Sweden), latex 
agglutination testing (Sweden), and immuno-turbidimetric testing (Finland), 
performed twice, at least 3 months apart. For study I and II, analyses of antinuclear 
antibodies (ANA) were performed twice, at least 3 months apart at the local 
laboratory. Each physician interpreted the results of the ANA and RF analyses as 
positive or negative according to the reference values used by the local laboratory. In 
Sweden, Denmark, Finland, and Trondheim, Norway, ANA were measured using 
immunofluorescence on HEp-2 cells (IF-ANA). In Tromsø, Norway, an ANA 
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enzyme-linked immunosorbent assay (ELISA-ANA) was used; these results were later 
excluded from the analyses in study I and II, due to the limited clinical value in JIA 
(295). In study III, ELISA-ANA, IF-ANA and AHA were analyzed in serum samples 
collected within the first year after disease onset. ELISA-ANA and IF-ANA were 
performed at the same laboratory technicians at the same laboratory and during a short 
time period at St. Olav’s Hospital in Trondheim, Norway, and the results were 
evaluated by Torolv Moen, one of the co-authors of the paper. AHA analyses were 
performed by one laboratory technicians and Ellen Nordal at the same laboratory and 
during a short time period at University of Tromsø, Norway. Details regarding the 
analyses and kits are given in the paper on study III. The control sera in study III were 
collected in order to provide information on the presence of ELISA-ANA, IF-ANA, 
and mean serum values of AHA in a healthy childhood population. The control sera 
were obtained from routine blood tests in 58 children undergoing elective outpatient 
procedures, with no diagnosis of inflammatory diseases. 
 
 
3.3 Data base and data handling  
A 4D database was designed specifically for the Nordic JIA study. Patient data from 
each visit was entered into the data base and stored at the participating centers. By the 
end of 2008 all data were sent from the study centers to Tromsø, Norway. The data 
were transferred to Excel 2002 for Windows and pooled for a common Nordic data-
file. Using the Excel file, all patient data were scrutinized for all disease descriptors 
and JIA categories decided at each visit by Ellen Nordal. For the majority of patients 
JIA categories were determined separately by Ellen Nordal and Lillemor Berntson, one 
of the co-authors of the papers. A few differences were found, mainly due to the 
updated ILAR criteria published in 2004, discarding the influence of psoriasis in a 
second degree relative. The discrepancies were settled by joint discussion and 
evaluation. Data regarding remission status recorded by the examining physician was 
cross-checked for inconsistencies with disease activity variables; active joint count, 
inflammatory markers and patient/parent and physicians VAS scales should all be zero 
 69 
according to the definitions of inactive disease and remission (175). Any 
inconsistencies were noted and participating centers asked for clarifications.  
 
 
3.4 Statistical methods 
Statistical analyses were performed using Stata version 10, 11 and 12 software, and 
details of the statistical analyses are described in the method sections of the papers. 
Descriptive statistics were used to summarize the clinical characteristics of the 
population and measures of disease activity. Chi-square and Fisher’s exact tests were 
used as appropriate for comparison of dichotomous variables, and the Mantel-Haentzel 
method was used for stratified analyses to control for confounding. The Mann-
Whitney U test was used for comparing medians for skewed data. The Student’s t-test 
and analysis of variance, with Bonferroni contrasts, were used to compare means in 
continuous outcome variables between groups, logarithmic transformation of the 
variable was carried out, and geometric means reported for skewed data when 
appropriate. Odds ratios (OR) with 95% confidence intervals (CI) were calculated 
using logistic regression. Linear mixed model analyses of z scores were used to 
account for dependence between repeated measures within study participants over 
multiple visits in study II. Bland-Altman plot was used to assess the magnitude of any 
systematic difference and random error between the two JADAS measures in study II. 
Sensitivity, specificity, the likelihood ratio (LR), and the positive and negative 
predictive values were calculated to describe the test performances of predictors of 
uveitis in study III. Receiver operating characteristics (ROC) curve and the 
corresponding area under the curve (AUC) was used to assess the sensitivity and 
specificity of AHA as a predictor of uveitis in study III. P-values less than 0.05 were 




3.5 Ethical considerations 
Approval from the Regional Committee for Medical Research Ethics of Northern 
Norway and the corresponding ethic committees and data inspectorate agencies of 
each participating country was granted. Written informed consent was obtained from 
the parents of children younger than age 16 years and from the children who were age 
16 years or older. 
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4 SUMMARY OF THE RESULTS 
Paper I 
Ongoing Disease Activity and Changing Categories in a Long-Term Nordic 
Cohort Study of Juvenile Idiopathic Arthritis.  
Ellen Nordal, Marek Zak, Kristiina Aalto, Lillemor Berntson, Anders Fasth, Troels 
Herlin, Pekka Lahdenne, Susan Nielsen, Bjørn Straume and Marite Rygg for the 
Nordic Study Group of Pediatric Rheumatology. Arthritis Rheum 2011;63(9):2809-18. 
 
• In this study 500 children was included, 440 (88.0%) of these had repeated 
visits, with the last visit occurring at least 7 years after disease onset (median 98 
months, range 84–147 months).  
• Changes in the International League of Associations for Rheumatology (ILAR) 
category during the disease course were observed in 10.8% of the children, and, 
in addition, extended oligoarthritis developed in 34.7% of the group with 
oligoarticular JIA.  
• During the observation period, 58.0% of the children were treated with disease-
modifying antirheumatic drugs, including biologic medications. 
• JIA-related damage developed in 22.9% of the children.  
• Ongoing disease activity was mostly mild, as shown by low median scores of 
disease activity measures at the final study visit, although considerable 
variation was found. 
• At the last followup visit 4.8% of the children reported absence from school or 
work for >5 days during the previous 2 months, and 76.7% of the school-age 
children participated fully in physical education, while 17.2% participated 
partly and 6.0% did not participate.   
• At the last followup visit, remission off medication was observed in 42.4% of 
the children, 8.9% were in remission on medication, and 48.7% were not in 
remission.  
• The highest rates of remission were observed in patients with persistent 
oligoarthritis and in those with systemic JIA. 
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Paper II 
Validity and predictive ability of the Juvenile Arthritis Disease Activity Score 
(JADAS) based on C-reactive protein in a population-based Nordic cohort of 
juvenile idiopathic arthritis.  
Ellen Nordal, Marek Zak, Kristiina Aalto, Lillemor Berntson, Anders Fasth, Troels 
Herlin, Pekka Lahdenne, Susan Nielsen, Suvi Pältoniemi, Bjørn Straume and Marite 
Rygg for the Nordic Study Group of Pediatric Rheumatology. Ann Rheum Dis 2011; 
(accepted for publication). 
    
• Of 389 children with available JADAS score at the first study visit, the 
correlation between JADAS27 based on CRP and JADAS27 based on ESR was 
r = 0.99, whereas the correlation between CRP and ESR was r = 0.57. 
• Children with higher JADAS scores had increased risk of concomitant pain, 
physical disability and use of disease-modifying antirheumatic drugs 
(DMARD).  
• Higher JADAS score at a study visit the first year after onset of disease 
significantly predicted physical disability, damage, and no remission off 
medication at the final study visit (median 8 years after disease onset). This 
early high JADAS score also predicted use of DMARD during the disease 
course.  
• Sensitivity to change, demonstrated as change in JADAS score compared to the 
American College of Rheumatology paediatric measures of improvement 




Biomarkers of chronic uveitis in juvenile idiopathic arthritis: predictive value of 
antihistone antibodies and antinuclear antibodies.  
Ellen Nordal, Nils T. Songstad, Lillemor Berntson, Torolv Moen, Bjørn Straume and 
Marite Rygg. J Rheumatol 2009;36(8):1737-43. 
 
• Chronic uveitis developed in 16 of 100 children with JIA, and acute uveitis in 
two children. 
• Chronic uveitis developed in 14 of 68 children with positive 
immunofluorescence titer of ANA ≥80, and in 13 of 44 children with 
antihistone antibodies ≥8 U/ml. 
• Antihistone antibodies were found in higher proportions in children with uveitis 
(mean 12.4 U/ml), than in those with JIA and no uveitis (mean 6.9 U/ml) or in 
healthy controls (mean 4.3 U/ml). 
• All children with chronic uveitis had either a positive immunofluorescence titer 
of ANA ≥80 and/or positive antihistone antibodies ≥8 U/ml. 
• Young age at onset of arthritis, presence of IF-ANA titer ≥320, and antihistone 
antibodies ≥30 U/ml were significantly associated with development of uveitis, 
but there were no association to female gender or oligoarticular onset of JIA. 
• Antinuclear antibodies (ANA) tested by ELISA-technique was positive in four 
of the 100 sera from children with JIA, and was not associated with uveitis.  
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5 GENERAL DISCUSSION 
The present study contributes to the current understanding of JIA by describing disease 
outcome the first eight years of disease course in a population-based setting. The 
change in disease categories over time challenges the present ILAR classification 
criteria. A low level of disease activity was found eight years after onset, although 
there was a considerable range in functional disability, pain and general impact of the 
disease. The composite disease activity measure JADAS can be an important clinical 
tool and was shown valid in a population-based setting. ANA method is important in 
predicting uveitis development in JIA. Our findings on a high rate of non-remission 
support the understanding of JIA as a long-standing chronic disease, and a significant 
proportion of the children in our cohort had some disease-related damage.  
  
5.1 Strengths and limitations 
The population-based setting is a major strength of the study. The cohort is derived 
from a defined population, which enables extrapolation of the results beyond our study 
group. Our cohort is prospectively collected and followed longitudinally over many 
years. Heredity and a broad range of detailed clinical information were thoroughly 
registered to ensure a well-characterized cohort. Recently developed disease activity, 
damage and remission measures were used.  
 
A limitation in our material is a small number of patients in some of the disease 
categories. This should be kept in mind when interpreting findings in the systemic, the 
polyarticular RF-positive and the psoriatic arthritis category. The first study visit often 
took place after the initial peak of disease activity, which may be a limitation for 
prognosis studies on baseline predictors. The first study visit was timed approximately 
six months after disease onset, when data to assess JIA category were available, since 
the study initially focused on incidence and classification issues. However, clinical 
information at the first registration was then collected for the whole initial period of 
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the disease. Because cases were collected at referral centers, the mildest cases may not 
have been included, inflicting a risk of selection bias towards more severe disease.  
 
 
5.2  Methodological considerations 
5.2.1 Choice of study design  
Methodological differences are a major obstacle when comparing information on 
incidence, disease course and outcome of JIA from different studies. NoSPeR has 
chosen to perform a longitudinal population-based cohort study in the Nordic 
countries. The strengths of a longitudinal cohort study are the possibilities to identify 
baseline predictors of certain outcomes such as development of uveitis or severe 
disease activity and damage. In order to collect the full spectrum of the disease and 
precisely describe incidence, course and outcome, the population-based approach is 
necessary (158).  
 
Traditionally many studies on JIA have been case series or cross-sectional, usually 
retrospective studies from tertiary referral centers, collecting only the most serious 
cases. Selection bias has clearly been a problem. Milder clinical cases might never be 
referred to a pediatric rheumatologist and will be lost in referral-based retrospective 
studies. There is a bias towards lower rates of the milder oligoarticular disease and 
higher rates of seriously ill systemic JIA in the literature, especially in older studies 
(296). The uniform organization of health care system in the Nordic countries provides 
unique opportunities to minimize the problem of selection bias, and epidemiologic 
studies of the incidence and natural history of JIA in a geographically defined 
population can be performed (24, 44, 122). 
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5.2.2 Population-based approach 
We have tried to be as population-based as possible. But is our study truly population-
based? A population-based study must be able to define and characterize its study 
population. In the geographic areas of our study, baseline demographic data as total 
number of inhabitants, age and gender distribution are available. A critical question is 
if all eligible children in these areas were included? Possible reasons for missing cases 
is that; 1) cases are undiagnosed or not referred, 2) cases are referred to other 
specialists than the participating centers, 3) cases are not correctly diagnosed at the 
participating center (most centers are general pediatric departments with pediatric 
rheumatologists in the staff), and 4) cases are refusing to participate.  
 
Undiagnosed cases are probably few, because the Nordic health care systems include 
regular checkups at a child health centre. Health care facilities at school, the general 
practitioner and specialist care are easily available, mostly governmental and all free 
of charge for children. Most children with a long-standing complaint will probably be 
found and referred. From a previous study of JIA in the region of Northern Norway, 
the prevalence show overlap with the 95% CI of truly population-based prevalence 
studies in Australian and Belgian school children, indicating that at least in this region 
most of the JIA cases are probably referred (102, 159, 163, 164). The possibility of 
missing milder cases can still not be excluded, as long as all children in the area were 
not examined by a pediatric rheumatologist. 
  
Referral of all eligible cases to the study centers were our aim. Measures were taken to 
include only geographical areas where the centers had a tradition over many years to 
diagnose and treat all patients with suspected rheumatic diseases in their catchment 
area. As previously described, all the collaborating departments, general practitioners 
and all private specialist clinics in the regions received repeated written information on 
the ongoing JIA study. Some regions (Nord-Trøndelag, Møre- og Romsdal, East 
Denmark) had the experience that a few incident cases from their region were referred 
to other hospitals outside the study centre. The main outcomes of the subgroup from 
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these centers were analyzed separately without significant differences in rates of 
oligoarticular category or remission status.  
 
In order to diagnose correctly case ascertainment was done by 20 experienced 
pediatric rheumatologists conducting the study, using uniform inclusion and 
assessment criteria. Efforts were taken to standardize clinical assessments to avoid 
misclassification, by meetings in the study group, comprising ten of these pediatric 
rheumatologists. Definitions were discussed to reduce inter-observer variations that 
might have influenced the quality of the data. Refusal to participate was not a major 
problem, because only three eligible patients did not wish to be included in the study, 
and 12 stated that they did not wish to continue in the followup study. 
 
The population-based setting is clearly important for validity of the outcome data of 
study I. This also applies for the study on biomarkers for uveitis in study III, but the 
children took part only if there were an available blood sample and an informed 
consent for this particular study. No statistically significant differences in the rate of 
uveitis or oligoarticular category were however found between the total Norwegian 
cohort and the participants in study III. In the JADAS validation study we considered 
the advantage of having more visits to analyze more important than the drawback of 
not keeping a strict population-based approach. This is because the correlations, 
predictive value and responsiveness to change of JADAS are validated against 
outcomes within the group. The inclusion period was therefore prolonged for study II 
to include all participants in the data base, also from time periods when the centers 
were not convinced that all eligible children with JIA were included. Nine tenths of the 
participants in Study II originate from the population-based cohort, so the study still is 
unique in its population-based approach compared to validations of JADAS in 
therapeutic trial settings.   
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5.2.3 Lost to followup  
Even though only 12% of the cases are lost to followup, they represent a risk of 
selection bias to our results. The group lost to followup has a higher age at onset, 
which may explain the higher presence of RF and the lower presence of ANA and 
uveitis. Study adherence is more difficult to achieve after transfer to adult 
rheumatology for the oldest patients, which is a problem also in other studies (63). 
  
5.2.4 Followup telephone interview  
Another limitation is that 14.5% of the children answered a telephone interview on 
their present health status, instead of a complete examination by a pediatric 
rheumatologist. However, the telephone interviews gave valuable information on the 
proportion of children that do not meet to clinical examination, and otherwise would 
be lost to followup. Telephone interviews were mainly performed in participants more 
than 16 years old. Studies on RA in adults have shown that the correlation is moderate 
to high between patient-reported swollen and tender joint count and a joint count 
performed by a rheumatologist (297).   
 
5.2.5 Data quality and data handling  
To what extent is our data accurate? At each visit clinical data from the examination, 
self-reported measures, and course since last study visit was recorded. When there is a 
long time span of more than 1-2 years since the last visit, data on disease course may 
be less trustworthy. Data handling from the study database via Excel to statistical 
software can be a potential source of systematic or random errors. For each participant 
a summary of all the study visits were made in Excel and manually updated based on 
all the registered visits. For each visit assessment, the JIA category was decided after 
consideration of all disease descriptors. Random errors may have occurred in this 
time-consuming work. However, JIA categories showed very consistent results, when 
compared to the JIA categories assessed by another researcher in our Nordic group 
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(Lillemor Berntson) working separately on data from the original 4D database two 
years earlier.  
   
 
5.3  Clinical implications of the results  
5.3.1 Changing categories and classification issues (study I and III) 
Stable homogeneous disease categories are a goal of a clinically useful and 
biologically relevant JIA classification (18, 31, 37). In line with other studies, we 
found that approximately a third of the children with initial oligoarticular disease 
developed an extended course with more than four joints involved (Study I) (39, 144, 
253). This change is implicit in the structure of the JIA classification (18). 
Oligoarticular persistent and oligoarticular extended categories are defined as two 
separate groups in JIA, and the former are shown to have a better prognosis both 
regarding remission rates and disease activity measures in many studies, including our 
study I (37, 41). This continuous change makes it impossible to give early prognostic 
information based on disease onset category in the large group with oligoarticular 
onset. There is therefore an ongoing search for early predictors of extended disease 
among children with oligoarticular disease the first six months (41, 298, 299).  
 
In addition to the children developing oligoarticular extended disease, JIA categories 
changed in 10.8% of the remaining children in our study. There is reason to believe 
that further change will occur over time, as change was observed throughout the 
observation period, and onset of psoriasis, enthesitis or related determinants in the 
children or their relatives may appear at any age. Biology is dynamic by nature, and 
the full clinical picture of a disease category may need time to develop (300). This a 
major challenge for a classification system based on clinical descriptors. Whether 
subdividing JIA according to psoriasis is worthwhile or not have been questioned 
(301).The enthesitis-related group has also been a special classification challenge 
(302). The proportion of children with enthesitis-related arthritis (ERA) increased 
from 7.7% six months after onset to 11.1% at the final study visit in our cohort. Flatø 
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et al described that the juvenile spondyloarthropathy (JSpA) group increased from 
11.1% to 26.4% in their cohort of 72 children reviewed after ten years (44). Andersson 
Gäre et al showed that the juvenile ankylosing spondylitis (JAS) group increased from 
4.8% to 12.1% over a seven-year period in a population-based study (137). These 
numbers may indicate that the present JIA classification possibly performs better in 
defining ERA at an early stage than the previous criteria of JSpA in JRA, and JAS in 
JCA.  
 
An early finding in our Nordic JIA cohort was a very high proportion of 
undifferentiated arthritis, and in almost half of these cases heredity for psoriasis in a 
second degree relative was the reason for exclusion from other categories (35). 
Heredity in second degree relatives is also difficult to ascertain, and this exclusion 
criterion was removed in the revised 2001 Edmonton criteria (18). In study I 
undifferentiated arthritis is still found in more than one of ten children, when heredity 
and disease descriptors have been carefully considered. In many clinical studies the 
undifferentiated category is not mentioned (42, 221, 237, 240, 252). This category is 
usually not part of therapeutic trials (183, 197). The complex exclusion criteria and the 
undifferentiated arthritis category are limitations in clinical use of the ILAR 
classification.  
 
How can classification of chronic childhood arthritis be improved, given the 
weaknesses pointed out above? In a search for a better classification of JIA, 
biomarkers are sought such as genetic associations or autoantibodies defining 
homogeneous groups. ANA is suggested as a determinant in classification by Ravelli 
et al, showing that ANA positive patients are a rather homogeneous group sharing 
many disease characteristics (303, 304). In study I we could not find that ANA was 
associated with any particular outcome pattern. We have later argued that ANA is not 
a suitable determinant, because it is a very unspecific immunologic marker; the sub-
specificity of ANA in JIA is mostly unknown, and reproducibility is a problem 
because there are several different methods of detection (Study III) (75, 79, 305). The 
immunofluoresence ANA test is operator-dependent and uniform cut-off values does 
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not exist (78, 79, 305). Martini et al suggest systemic arthritis, rheumatoid factor-
positive polyarthritis, enthesitis-related arthritis, and early-onset ANA-positive 
oligoarthritis as the more well-defined categories of JIA (37, 38). Less well-defined 
categories discussed are ANA-negative and/ or late-onset oligoarthritis, rheumatoid 
factor-negative polyarthritis and psoriatic arthritis (38).  
 
The ILAR classification has been criticized for being too complicated for regular 
clinical use (156). In adults new classification criteria for rheumatoid arthritis (RA) are 
recently agreed upon with a quite different focus (306). The main aim is to early 
diagnose and start DMARD treatment in those with risk of erosive arthritis. 
Rheumatoid arthritis is less heterogeneous than JIA, but is still called a “disease 
construct” (306). Also in JIA there is some evidence for benefit of early treatment. The 
recently published ACR treatment recommendations also suggest five JIA treatment 
groups; oligoarthritis, polyarthritis, sacroileitis and systemic JIA with or without active 
systemic features. The stated reason for this approach is that minimal evidence support 
differential treatment for many of the ILAR category distinctions (46). Multiple 
correspondence and cluster analyses of clinically well-characterized large cohorts of 
JIA may give valuable clues in elaborating a more homogeneous and biologically 
relevant JIA classification (303).  
 
Changing categories remains a problem, because JIA category at onset is used to guide 
therapeutic decisions and information on prognosis to the children and parents (51, 
307). Clearly, the existing JIA classification still does not provide biologically 
meaningful, easily identifiable and stable classification criteria. How to improve 
classification of JIA remains a difficult task, but a prerequisite is high-quality clinical 




5.3.2 Disease activity and functional ability (Study I and II) 
At the final study visit the disease activity measures in our cohort showed generally 
low scores, with median values mostly within the normal range, in line with other 
long-term studies (Study I) (39, 44, 47, 63, 237). Oen et al reported recently similar 
outcomes in a Canadian JIA inception cohort assessed within 18 months after the first 
disease onset (64).  
 
In the Nordic population-based setting JADAS was shown to be feasible and valid 
compared with other measures of disease activity not included in the score (Study II). 
Previous validations have mostly been done in more homogeneous cohorts with 
polyarthritis and high levels of disease activity, enrolled mostly from specialized 
tertiary pediatric rheumatology centers (257, 308). The Nordic JIA cohort was 
collected consecutively, and validation was performed in a heterogeneous group with 
all categories of JIA. Our cohort is dominated by children with low ongoing disease 
activity, representative of what we see in daily clinical work, and presumably relevant 
for many other pediatric rheumatology centers.  
 
In the clinic CRP may be a more easily available test than ESR. A blood sample can be 
taken from the finger tip instead of venopuncture in small children, results are rapidly 
available, and costs are comparable. The feasibility of JADAS increases when either 
CRP or ESR can be used. The close correlation of JADAS based on CRP and ESR, 
and the overall very close performance of the two measures, show validity of both 
measures. Our results indicate that the two measures also can be used interchangeable 
in the followup of the individual patient. This finding, however, should be confirmed 
in other studies before it can be generally recommended to use JADAS based on CRP 
and ESR alternating in the same patient to guide treatment decisions. A simplified 
JADAS version without inflammatory markers may be worth elaborating and 
validating, because an inflammatory marker is not always available in a clinical setting 
(257).   
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In the present and earlier studies, there have been minimal differences between the 
JADAS versions regarding validity and feasibility (Study II) (257, 308). For 
retrospective studies the JADAS based on maximum 10 joints may be preferred. It is 
possible to use also if the number of active joints, but not the exact joint is recorded. 
JADAS71 is a comprehensive score based on all 71 joints counted. JADAS27 is 
somewhat simpler and less tedious by counting fewer joints, but the clinician must 
have an easy system to be able to register if the involved joint is among the 27 joints 
counting in the score. For practical reasons agreement on which joint count to use 
should be standardized so that different studies can be compared, and we suggest 
JADAS27-CRP to be used as the standard version.   
 
5.3.2 Patient-reported outcome measures (Study I and II)  
The outcome measures that are most relevant to the patient’s own experience of health 
must have high priority in research (309). Several patient-reported outcome measures 
were used in Study 1 and II. Visual analogue scales were used for ratings of impact of 
the disease on overall well-being and pain in the previous week. Children’s ratings of 
pain are found to agree only moderately with ratings of their parents, whereas the 
ratings of fathers and mothers agree at a good level (310, 311). The standardized 
approach at all centers that these ratings were done by the children if aged more than 
nine years and by the parents in younger children, may therefore be important for 
validity of the data. 
 
Global assessment of the impact of the disease on overall well-being scored by the 
child/ parent and the physician’s rating of disease severity are two different concepts. 
The patient may have another perspective than the care-giver. In spite of these 
differences, patients’ and physicians’ global assessment VAS showed very similar 
median and interquartile scores at the final study visit in the total cohort.  
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In study I we chose to present the numbers of children with CHAQ >0, pain VAS >0, 
child/parents and physicians global VAS >0 and CHQ physical summary score <40 (-1 
SD of the mean score in a healthy reference population). The clinical significance of 
such low thresholds can be discussed, and CHAQ scores >0.5 may be a more 
meaningful measure of physical disability. Other measures of high disease activity 
such as JADAS27, present DMARD use, pain, and active joint counts showed 
however similar pattern in the different JIA categories (study I). Zero as a threshold 
for these measures has also been used in other outcome studies (49). CHAQ has also 
been criticized for having a ceiling effect and not being sensitive enough for the 
physical difficulties usually found in JIA (312). 
 
Approximately half of the patients in our cohort reported pain from the disease and 
that the disease had some impact on their daily life at the last study visit. These figures 
demonstrate that even though objective activity measures are low, many patients 
experience pain and less well-being. This important finding points to a clear impact of 
the disease and disease-related pain in daily living for these young people. In a 
Swedish population-based study Andersson Gäre et al found slightly higher median 
pain scores (0.1 for boys and 0.8 for girls, range 0-10) seven years after onset (47), and 
Minden et al found median pain score 1.0 (iqr 0-3.0) in their 16.5 year followup of a 
partly population-based, partly referral-based cohort (39). Advances in medical 
treatment may partly explain the lower scores in our cohort. Chronic pain is not 
restricted to children with JIA or other chronic diseases. Recent studies on pain in 
healthy adolescents show the prevalence of self-reported chronic musculoskeletal pain 
to be 33.4% (313). The children with JIA is however asked to rate pain related to their 
articular disease during the preceding week, and the pain scores show a close 
correlation with other measures of disease activity such as active joints, DMARD use 
and continuously active disease (Study I and II). 
 
Several authors report that disease activity explains only a modest proportion of pain 
experience in children with JIA (239, 314, 315). Thastum et al has shown that health 
beliefs and pain-coping strategies are associated to disease-related pain in JIA (238, 
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315, 316). They also found that children with high pain ratings in disproportion with 
other disease activity measures, compared to other children with JIA, perceived 
themselves as more disabled, expressed that pain signified more damage and that 
exercise therefore had to be restricted (315). Schanberg et al found parent and familial 
pain history to be prevalent and to influence pain experiences in children with JIA 
(317, 318). Pain sensitizing may be a mechanism explaining lower pain thresholds in 
children with JIA compared to healthy peers (239). Increasing pain is reported in both 
JIA and in healthy children with increasing age in girls (239, 313). Assessment of pain 
and also pain-specific beliefs may be important in optimal management of children 
with JIA in order to identify and offer behavioral intervention to the subgroup of 
children whose pain experience is in discordance with the actual disease activity (238).  
 
5.3.3 Treatment (Study I and II)  
Intraarticular corticosteroids (IACS) were used in three of four children in our cohort, 
and the maximum number of injections in one child was 70 (Study I). Solari et al 
report a similarly high rate of children receiving IACS (79%), while most other studies 
report much lower rates (63, 237). IACS may be a valuable tool with limited side 
effects in reaching the goal of inducing early inactive disease, and the use is in line 
with present recommendations (46). The total number of 32.3% using systemic 
glucocorticoids may reflect short-term use, because the 1.1% presently using at the last 
followup is low compared to other followup studies (3.2-13%) (63, 64, 237).   
 
There are indications that early DMARD treatment may change the disease course. 
Totally 58.0% of the children in our study had ever used DMARD and 30.5% were 
using DMARD at the final study visit. These numbers are higher than older studies 
and in fact most other outcome studies except for Solari et al and Flatø et al reporting 
outcomes from tertiary center samples (44, 48, 63, 64, 237). MTX is recommended as 
the first choice DMARD in JIA, and it is the most commonly used systemic drug in 
our cohort (46, 192). Oen et al found in their retrospective cohort that use of 
methotrexate more than quadrupled between those diagnosed in the 1990’s compared 
 86 
to the 1970’s (63). In the study of Flatø et al hydroxychloroquine was the most 
commonly used DMARD during the 1980’s (44). There are no firm evidence of 
efficacy of hydroxychloroquine as monotherapy in JIA, and this drug is not often used 
in our study (205). However, a recent Finnish RCT showed combination therapy of 
hydroxychloroquine, salazopyrine and MTX to be superior to MTX alone, but inferior 
to infliximab and MTX (204). Present use of DMARD is in our study chosen as a 
marker of severe disease. The use of biologic agents in pediatric rheumatology 
represents the beginning of a new era in medical treatment of JIA, and etanercept was 
introduced at the same time as our study started (183). Indications and approvals have 
been widened as efficacy and safety data on biologic agents in children have emerged 
(183, 209, 319). The use of biologic medication was increasingly used during the study 
period. In case of unsatisfactory response to MTX, early use of biologic agents is 
presently recommended (46). 
 
In 2008 the FDA issued a “black box warning” on increased risk of cancer in children 
with inflammatory bowel disease or JIA treated with TNF-blocking agents (REF). Half 
of the malignancies were lymphomas, and most cases had received concomitant 
immunosuppressive treatment (321). The background risk of malignancies in JIA has 
not been known until Simard et al reported findings in a case-control study of 9027 
cases of JIA in a Swedish population (248). Patients with JIA identified before 1987 
were not at increased risk of cancer, whereas JIA identified in 1987 and thereafter was 
significantly associated with lymphoproliferative malignancies and overall cancer. The 
overall risk is low, but still this is a striking finding of increased cancer risk in the 
period when MTX was the dominating DMARD, with no change the last decade after 
introduction of biologic agents (248). A large international long-term surveillance 
study is started to clarify whether this is related to the disease per se or to the treatment 
with methotrexate, biologics or other antiinflammatory agents (249). 
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5.3.4 Remission rates and prognosis (Study I and II)  
The first question from parents of children with newly diagnosed JIA is often “will my 
child get well?” Up to the 1990’s a prevailing notion was that 80% of the children 
would “out-grow” their disease (208). Our study showed that less than half of the 
children are in remission off medication eight years after disease onset. According to a 
retrospective study by Wallace et al, even fewer children had continuous inactive 
disease when assessed during longer observation periods (42). Recent followup studies 
have shown that JIA has a chronic course in the majority of children, with fluctuating 
disease activity resulting in cycles of active and inactive periods (45, 63, 236, 322). As 
mentioned there are indications that early treatment may modify the disease course in 
a milder direction (176, 323, 324). The question to what extent earlier effective 
treatment may lead to longer periods of inactive disease still remains largely 
unanswered. If this presumption can be verified, there is an urgent need for robust 
baseline predictors of an ongoing disease course to identify children in need of early 
aggressive treatment. The baseline JADAS score is shown to be associated with 
remission status at the last study visit (Study II). 
  
The remission rates of the children in our study showed considerable differences 
depending on JIA category at the final study visit (Study I). In the oligoarticular 
extended group only 21.3% were in remission. In fact, there was a trend that children 
in this category had the most severe prognosis in terms of pain and global assessment 
of disease impact in daily life according to the patient or parent. This finding is in line 
with other studies, and emphasizes the need for early predictors of extended or 
persisting oligoarticular course, because less aggressive treatment has usually been 
recommended upfront in initially oligoarticular disease (45, 46, 192, 196). Barnes et al 
showed in recent onset arthritis that gene expression profiles of peripheral blood 
mononuclear cells of oligoarticular persistent patients have a characteristic pattern 
(325). Similar biologic differences predicting extended oligoarticular disease were 
reported by Hunter et al, examining early samples of synovial fluid cellular 
composition and gene expression (41). A timely question is if DMARD are started too 
late in extended oligoarthritis due to a false presumption of a better prognosis in 
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oligoarticular onset? In this way the early “window of opportunity” to modify the 
disease course might be missed.  
 
A surprisingly high remission rate of 83.3% was found in our cohort of systemic JIA 
(Study I). Similar results are also found in some other followup studies (45, 64). 
Persistent arthritis in systemic JIA can be very resistant to treatment, and a severe 
prognosis is reported from many tertiary care centers seeing the most difficult cases 
(196, 326, 327). This high remission rate of systemic JIA in a population-based 
setting, also in children not treated with biologic agents, should be kept in mind when 
interpreting data from newer studies with biologic agents as first-line therapy (193).  
 
5.3.5 Damage (Study I and Study II) 
Inducing early remission and avoiding damage are the main goals of JIA treatment 
(172). Damage in JIA can be defined as disease-related long-term/ irreversible 
conditions or sequelae (243). There are few reports on damage in JIA according to 
JADI, because the damage index is recently developed (245). Available reports from 
the Italian validation study, a Brazilian cohort of oligoarticular JIA, a Serbian and an 
Indian study showed that between 37 - 61% of the children had damage according to 
the JADI (237, 243-245, 328). JADI measures a broad range of damage from serious 
visual impairment or joint replacements, to less serious leg length discrepancies or 
subcutaneous atrophies. Summary scores of such varied sequelae should be interpreted 
cautiously. In our cohort higher JADAS score at the first visit was shown to predict 
damage, and more than one in five children developed some JIA-related damage 
(Study I and II). A clinical implication is that more aggressive treatment may be 
needed in children with higher baseline JADAS score, not only to treat the arthritis, 




5.3.6 Predictors (Study I, II and III) 
The diverging clinical spectrum of disease course in JIA and the potent treatment 
possibilities implies a strong need for robust predictive baseline factors. The predictive 
value of JADAS regarding outcome measures as physical disability, pain, DMARD 
treatment, and remission was shown in the validation study (Study II). In addition to 
assessing JADAS validity, this shows that early disease activity is predictive of disease 
course and outcome in a longer term. Myeloid-related protein (MRP)-8/ MRP-14 (also 
called calprotectin) is a biomarker shown to predict the risk of flare after methotrexate 
withdrawal, and has been studied as a baseline predictor of severe disease course (329, 
330). JADAS and MRP8/ MRP14 may simply both be indirect measures of high level 
of inflammation, predicting severe ongoing disease. A higher percentage of active 
disease in the first two years is shown to be related to an unremitting disease course 
the following three years (40, 177). Other studies have shown that CRP, ESR, RF, 
early radiographic erosions, and hip arthritis are predictors of severe disease (44, 46, 
49). The newest treatment recommendations for JIA are based on early assessment of 
such risk factors from the different treatment groups (46). 
 
Biomarkers of uveitis were studied in the Norwegian cohort of children with JIA 
(Study III), because early diagnosis and initiation of treatment in this potential sight-
threatening complication is crucial (135). Minden et al reports that among the 14% 
with uveitis in their JIA cohort, half of the patients developed complications and of 
these 80% had visual impairment (39). In line with other studies we found that early-
onset arthritis was an important risk factor of chronic uveitis. In our study ELISA 
ANA is not associated with uveitis development in JIA. A change in ANA method of 
analyses in the laboratory may not be considered important by the clinician. In the case 
of ANA a change from immunofluoresence to ELISA analyses will result in increased 
frequency of negative ANA for children with JIA. A negative ANA implies less 
frequent eye examinations, according to most screening guidelines (150). This 
message has important clinical implications, which must be emphasized for clinicians 
interpreting an ANA result to avoid delayed diagnosis of uveitis. Given the 
weaknesses of ANA immunofluoresence analyses regarding reproducibility, ELISA 
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antihistone antibodies may be an alternative biomarker of development of chronic 
uveitis. The combinations of positive antihistone antibodies and IF-ANA are an 
interesting option that identified all children developing uveitis in our study. This 
result needs confirmation in further studies. 
 
In relation to the suggestion from Martini and Ravelli et al on ANA identifying a 
homogeneous subset of children with JIA, the presence of IF-ANA was not associated 
to remission status in our study. However, fewer children with young age at disease 
onset achieved disease remission off medication compared with children with late-
onset disease, independent of ILAR categories (Study I).  
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6 CONCLUSION 
Outcome in terms of disease activity and remission rates are reported in this 
population-based longitudinal cohort study. Our findings challenge the present 
classification criteria for JIA in several ways; 1) substantial change in the categories is 
shown to occur during the disease course, 2) more than one of ten children are 
classified to have undifferentiated arthritis, and 3) extended oligoarthritis and RF-
negative polyarthritis have very similar outcome.  
 
Almost one third of the children were still using regular medication and 58.0% had 
used DMARD during the disease course. One of five children had some JIA-related 
damage. The chronicity of JIA is shown as 57.6% of the children were not in 
remission off medication eight years after disease onset. 
 
The composite disease activity measure JADAS were found feasible and valid in this 
population-based setting. JADAS based on CRP correlate closely with JADAS based 
on ESR, and both measures can be used to quantify disease activity in JIA.  
 
Biomarkers and early predictors of uveitis were evaluated. The main findings were 
that antihistone antibodies ≥8 U/ml tested by ELISA and ANA titer ≥80 tested by 
immunofluorescence have similar test properties as significant predictors of uveitis 
development. Early-onset arthritis was also a significant predictor of uveitis. ANA 
performed by ELISA analysis was not associated with uveitis 
  
This study underlines the chronicity of JIA and the need for long-term followup into 
adulthood in order to avoid damage and further improve outcome. 
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7 FUTURE STUDIES  
In our cohort there are several further possibilities for research in JIA. The length of a 
longitudinal outcome study can always be even longer, and plans are already made for 
the next followup study of the 500 participants included at baseline. The main 
challenge will be to avoid a high rate of participants lost to followup, as years pass by 
and many participants may move or become busy with education and work in early 
adulthood.  
 
Potential predictors of disease outcome regarding extended or persistent course in 
oligoarthritis and remission status will be explored, using the collected biologic 
material. The aim is to find robust biomarkers to propose groups for tailored treatment. 
 
Potential predictors or descriptors in JIA classification such as young age, ANA 
positivity and specific joint involvement may be investigated in our cohort. Defined 
cut-offs of JADAS for different levels of disease activity and inactive disease should 
be elaborated, and would be useful in monitoring treatment. A disease activity measure 
without an inflammatory marker may also be clinically useful, because blood sampling 
is not always performed at visits. There are few population-based studies on uveitis in 
JIA, and we would like to further study the development and implications of uveitis. 
Patient-reported outcome and quality of life according to the different clinical 
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